

# Best Available Copy

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
30 January 2003 (30.01.2003)

PCT

(10) International Publication Number  
**WO 03/008535 A2**

- (51) International Patent Classification<sup>7</sup>: **C12N**
- (21) International Application Number: **PCT/IL02/00606**
- (22) International Filing Date: **21 July 2002 (21.07.2002)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
**60/306,462** **20 July 2001 (20.07.2001)** **US**
- (71) Applicant (*for all designated States except US*): **TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD.** [IL/IL]; Senate House, Technion City, 32 000 Haifa (IL).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **GEPSTEIN, Lior** [IL/IL]; 26 Raanan Street, 34 384 Haifa (IL). **KEHAT, Izhak** [IL/IL]; 9 Horev Street, 34 341 Haifa (IL). **IT-SKOVITZ-ELDOR, Joseph** [IL/IL]; 42 SheErit HaPleta Street, 34 987 Haifa (IL). **AMIT, Michal** [IL/IL]; 261 Yuvalim, 20 142 Misgav (IL).
- (74) Agent: **G. E. EHRLICH (1995) LTD.**; 28 Bezalel Street, 52521 Ramat Gan (IL).

- (81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHODS OF GENERATING HUMAN CARDIAC CELLS AND TISSUES AND USES THEREOF

(57) Abstract: A method of generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype is disclosed. The method comprises (a) partially dispersing a confluent cultured population of human stem cells, thereby generating a cell population including cell aggregates; (b) subjecting said cell aggregates to culturing conditions suitable for generating embryoid bodies; (c) subjecting said embryoid bodies to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of said embryoid bodies, said culturing conditions suitable for inducing cardiac lineage differentiation including adherence of said embryoid bodies to a surface, and culture medium supplemented with serum, thereby generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype.

WO 03/008535 A2

## METHODS OF GENERATING HUMAN CARDIAC CELLS AND TISSUES AND USES THEREOF

This application claims the benefit of priority from U.S. Provisional  
5 Patent Application No. 60/306,462, filed July 20, 2001.

### FIELD AND BACKGROUND OF THE INVENTION

The present invention relates to methods of generating cardiac cells and  
tissue by *in-vitro* culture of differentiable cells, to methods of using such cardiac  
10 cells and tissues to repair dysfunctional human cardiac tissues and to test the  
effect of treatments on human cardiac cells and tissues, and to characterize  
biological states or processes of cardiac cells and tissues. More particularly, the  
present invention relates to methods of generating highly differentiated, highly  
functional, proliferating cardiac cells and tissues by *in-vitro* culture of human  
15 embryonic stem cells, and to methods of using such cardiac cells and tissue to  
repair human cardiac tissue, to test the therapeutic effect and toxicity of  
pharmacological and electrical treatments on human cardiac cells and tissues, and  
to model the development and physiology of cardiac cells and tissues *in-vitro*.

Heart disease is the predominant cause of disability and death in all  
20 industrialized nations, and, in addition, the incidence of heart failure is increasing  
in the United States, with more than half a million Americans dying of this  
disease yearly (Braunwald E., 1997. N Eng J Med. 337:1360; Eriksson H., 1995.  
J Inter Med. 237:135). In addition, in the United States, cardiac disease accounts  
for about 335 deaths per 100,000 individuals (approximately 40 % of the total  
25 mortality) overshadowing cancer, which follows with 183 deaths per 100,000  
individuals.

Four categories of heart disease account for about 85–90 % of all cardiac-  
related deaths. These categories are ischemic heart disease, hypertensive heart  
disease and pulmonary hypertensive heart disease, valvular disease, and  
30 congenital heart disease. Ischemic heart disease alone, notably myocardial  
infarction, accounts for about 60–75 % of all deaths caused by heart disease.

Despite considerable advances in the diagnosis and treatment of heart disease, cardiac dysfunction following myocardial infarction remains a major cardiovascular disorder that is increasing in incidence, prevalence, and overall mortality. Myocardial infarction is a life-threatening event responsible for cardiac sudden death or heart failure involving blockage of cardiac blood vessels, and concomitant death and damage of cardiac tissues induced by oxygen deprivation. Following acute myocardial infarction, dead and damaged cardiac muscle cells (cardiomyocytes) are gradually replaced by fibroid nonfunctional tissue, and in many cases ventricular remodeling results in wall thinning and loss of regional contractile function. One of the factors that renders ischemic heart disease, such as myocardial infarction, so devastating is the extremely low capacity of healthy adult cardiomyocytes to divide, and thus repopulate areas of ischemic heart damage. Thus, cardiac cell loss as a result of injury or diseases such as myocardial infarction is essentially irreversible. When occurring at critical sites in the conduction system of the heart, such cell loss or injury may lead to inefficient rhythm initiation or impulse conduction. Consequentially, these processes may result in abnormally low heart rate (bradyarrhythmias) requiring the implantation of a permanent pacemaker.

Human to human heart transplants have become the most effective form of therapy for severe heart damage. Heart transplantation, however, suffers from numerous drawbacks. For example, this form of therapy is severely limited by the scarcity of suitable donor organs, and, in addition, the expense of heart transplantation prohibits its widespread application. Another unsolved problem is graft rejection. Foreign hearts are poorly tolerated by the recipient and are rapidly destroyed by the immune system in the absence of immunosuppressive drugs, such as cyclosporin, the immunosuppressant of choice. However, drugs such as cyclosporin severely impair immune responses such as those against bacterial and viral infections, thereby placing the transplant recipient at risk of infection. Yet further complications caused by cyclosporin include hypertension, renal dysfunction, rapidly progressive coronary atherosclerosis, and

immunosuppressant-related cancers. Thus, alternatives to heart transplantation for treating cardiac disorders are urgently required.

One approach for overcoming deficits of cardiac transplantation, of treating cardiac disease has suggested transplantation of adult cardiomyocytes into affected cardiac tissues since, for example, functional engraftment of such cells or tissues within dead or dysfunctional cardiac tissues could restore impaired cardiac function. However, such approaches are hampered by the inability of adult cardiomyocytes to proliferate, and hence to efficiently colonize and regenerate, dead or damaged cardiac tissue, or to remodel deformed cardiac tissue.

The extremely low capacity of adult cardiomyocytes to proliferate further represents an obstacle to approaches attempting to utilize *in-vitro* culture thereof to generate cells and tissues suitable for testing the therapeutic effect and toxicity of treatments, such as pharmacological and electrical treatments, on cardiomyocytic cells and tissues, and to model the development and physiology of such cells and tissues.

Several prior art approaches have attempted to use *in-vitro* culture of differentiable cells (cells having a capacity to differentiate) to generate cardiac cells or tissue suitable for treating human cardiac disorders, and for testing the effects of treatments, such as pharmacological and electrical treatments, on human cardiac tissues.

One approach has utilized delivery of mouse embryonic/fetal cardiomyocytes into syngeneic host myocardium in an attempt to demonstrate the engraftment capacity of such developing cells (Soonpaa, M.H. *et al.*, 1994. Science 264:98).

Yet another approach has utilized transplantation of rat fetal myocardial tissue into infarcted rat myocardium in an attempt to repair such infarcted tissues (Leor, J. *et al.*, 1996. Circulation 94(suppl. II):II-332-II-336).

Still another approach has used culturing of mouse embryonic stem cells in attempts to generate cardiomyocytic cells and tissue (Igelmund *et al.*, 1999.



Flugers Arch. 437:669; Maltsev V.A. *et al.*, 1994. Circ. Res. 75:233; Metzger JM. *et al.*, 1995. Circ Res. 76:710; Sánchez A. *et al.*, 1991. J Biol Chem. 266:22419).

5 A further approach has employed genetic transformation of murine embryonic stem cells with a fusion gene consisting of the alpha-cardiac myosin heavy chain promoter and a cDNA encoding aminoglycoside phosphotransferase to generate cardiomyocytic cells (Klug, M.G. *et al.*, 1996. J. Clin. Invest. 98:216).

10 Still a further approach has utilized suspension culture of cystic human embryoid bodies in an attempt to generate cardiomyocytic cells and tissues (Itskovitz-Eldor *et al.*, 2000. Mol. Med. 6:88-95).

However, all of the aforementioned approaches are unsatisfactory for providing cells and tissues suitable for human application; approaches utilizing genetic transformation entail safety risks, pose ethical concerns, and are labor  
15 intensive, administratively difficult to implement, and unproven in human systems; and approaches utilizing suspension culture of cystic human embryoid bodies are inefficient, have not demonstrated a satisfactory range of cardiac specific structure and function, have not provided isolated human cardiac cells and tissues, have not demonstrated long term cardiac functionality *in-vitro*, and  
20 have not demonstrably provided cells and tissues capable of conferring cardiac function when engrafted *in-vivo*.

Thus, all prior art approaches have failed to provide an adequate solution for using *in-vitro* culture of differentiable cells to generate cardiac cells and tissues suitable for treating human cardiac disorders, for testing the therapeutic  
25 and toxic effects of treatments, such as pharmacological and electrical treatments, on human cardiac cells and tissues, and for modeling processes such as development and physiology of human cardiac cells and tissues.

There is thus a widely recognized need for, and it would be highly advantageous to have, a method of using *in-vitro* culture of differentiable cells to  
30 generate cardiac cells and tissues devoid of the above limitation.

SUMMARY OF THE INVENTION

According to one aspect of the present invention there is provided a method of generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype, the method comprising: (a) partially  
5 dispersing a confluent cultured population of human stem cells, thereby generating a cell population including cell aggregates; (b) subjecting the cell aggregates to culturing conditions suitable for generating embryoid bodies; and (c) subjecting the embryoid bodies to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of the embryoid  
10 bodies, the culturing conditions suitable for inducing cardiac lineage differentiation including adherence of the embryoid bodies to a surface, thereby generating cells predominantly displaying at least one characteristic associated with the cardiac phenotype.

According to further features in preferred embodiments of the invention  
15 described below, the method of generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype further comprises isolating the cell aggregates from the cell population prior to step (b).

According to still further features in the described preferred embodiments, the method of generating cells predominantly displaying at least one  
20 characteristic associated with a cardiac phenotype further comprises isolating the embryoid bodies prior to step (c).

According to still further features in the described preferred embodiments, the method of generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype further comprises screening  
25 and optionally isolating cells predominantly displaying at least one characteristic associated with a cardiac phenotype, the screening effected by at least one method selected from the group consisting of detection of mechanical contraction, detection of a cardiac specific structure, detection of a cardiac specific protein, detection of a cardiac specific RNA, detection of cardiac

specific electrical activity, and detection of cardiac specific changes in the intracellular concentration of a physiological ion.

According to still further features in the described preferred embodiments, the method of generating cells predominantly displaying at least one  
5 characteristic associated with a cardiac phenotype further comprises screening and optionally isolating cells substantially displaying proliferation.

According to another aspect of the present invention there is provided a method of generating tissue predominantly displaying at least one characteristic associated with a cardiac phenotype, the method comprising: (a) partially  
10 dispersing a confluent cultured population of human stem cells, thereby generating a cell population including cell aggregates; (b) subjecting the cell aggregates to culturing conditions suitable for generating embryoid bodies; and (c) subjecting the embryoid bodies to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of the embryoid  
15 bodies, the culturing conditions suitable for inducing cardiac lineage differentiation including adherence of the embryoid bodies to a surface, thereby generating tissue predominantly displaying at least one characteristic associated with the cardiac phenotype.

According to further features in preferred embodiments of the invention  
20 described below, the method of generating tissue predominantly displaying at least one characteristic associated with a cardiac phenotype further comprises isolating the cell aggregates from the cell population prior to step (b).

According to still further features in the described preferred embodiments, the method of generating tissue predominantly displaying at least one  
25 characteristic associated with a cardiac phenotype further comprises isolating the embryoid bodies prior to step (c).

According to still further features in the described preferred embodiments, the method of generating tissue predominantly displaying at least one characteristic associated with a cardiac phenotype further comprises screening  
30 and optionally isolating tissue predominantly displaying at least one

characteristic associated with a cardiac phenotype, the screening effected by at least one method selected from the group consisting of detection of mechanical contraction, detection of a cardiac specific structure, detection of a cardiac specific protein, detection of a cardiac specific RNA, detection of cardiac specific electrical activity, and detection of cardiac specific changes in the intracellular concentration of a physiological ion.

According to still further features in the described preferred embodiments, the method of generating tissue predominantly displaying at least one characteristic associated with a cardiac phenotype further comprises screening and optionally isolating tissue substantially displaying proliferation.

According to still another aspect of the present invention there is provided a method of characterizing a biological state or a biological process of cardiac cells or cardiac tissue, the method comprising: (a) partially dispersing a confluent cultured population of human stem cells, thereby generating a cell population including cell aggregates; (b) subjecting the cell aggregates to culturing conditions suitable for generating embryoid bodies; (c) subjecting the embryoid bodies to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of the embryoid bodies, the culturing conditions suitable for inducing cardiac lineage differentiation including adherence of the embryoid bodies to a surface, thereby generating the cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or the tissue predominantly displaying at least one characteristic associated with a cardiac phenotype; and (d) obtaining data characterizing the biological state or the biological process in the cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or the tissue predominantly displaying at least one characteristic associated with a cardiac phenotype.

According to further features in preferred embodiments of the invention described below, the method of characterizing a biological state or a biological process further comprises isolating the cell aggregates from the cell population prior to step (b).

According to still further features in the described preferred embodiments, the method of characterizing a biological state or a biological process further comprises isolating the embryoid bodies prior to step (c).

According to still further features in the described preferred embodiments, the method of characterizing a biological state or a biological process further comprises screening and optionally isolating cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or tissue predominantly displaying at least one characteristic associated with a cardiac phenotype, the screening effected by at least one method selected from the group consisting of detection of mechanical contraction, detection of a cardiac specific structure, detection of a cardiac specific protein, detection of a cardiac specific RNA, detection of cardiac specific electrical activity, and detection of cardiac specific changes in the intracellular concentration of a physiological ion.

According to still further features in the described preferred embodiments, the method of characterizing a biological state or a biological process further comprises screening and optionally isolating cells substantially displaying proliferation or tissue substantially displaying proliferation.

According to still further features in the described preferred embodiments, the method of characterizing a biological state or a biological process further comprises inducing the biological state or the biological process in the cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or the tissue predominantly displaying at least one characteristic associated with a cardiac phenotype.

According to still further features in the described preferred embodiments, the method of characterizing a biological state or a biological process further comprises co-culturing the cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or the tissue predominantly displaying at least one characteristic associated with a cardiac phenotype with primary cardiac cells or primary cardiac tissue prior to step (d).



According to still further features in the described preferred embodiments, the method of characterizing a biological state or a biological process further comprises transplanting the cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or the tissue predominantly displaying at least one characteristic associated with a cardiac phenotype into cardiac tissue of a recipient prior to step (d).

According to still further features in the described preferred embodiments, the biological state or the biological process is selected from the group consisting of cardiac specific mechanical contraction, a cardiac specific structure, expression of a cardiac specific RNA, expression of a cardiac specific protein, cardiac specific changes in the intracellular concentration of a physiological ion, cardiac specific electrical activity, and cardiomyogenesis.

According to still further features in the described preferred embodiments, the biological state or the biological process is cardiac specific electrical activity and obtaining data characterizing the biological state or the biological process is effected using a multielectrode array.

According to yet another aspect of the present invention there is provided a method of qualifying the effect of a treatment on a biological state or a biological process of cardiac cells or tissue, the method comprising: (a) partially dispersing a confluent cultured population of human stem cells, thereby generating a cell population including cell aggregates; (b) subjecting the cell aggregates to culturing conditions suitable for generating embryoid bodies; (c) subjecting the embryoid bodies to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of the embryoid bodies, the culturing conditions suitable for inducing cardiac lineage differentiation including adherence of the embryoid bodies to a surface, thereby generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or the tissue predominantly displaying at least one characteristic associated with a cardiac phenotype; (d) subjecting the cells predominantly displaying at least one characteristic associated with a cardiac

phenotype, or the tissue predominantly displaying at least one characteristic associated with a cardiac phenotype to the treatment; and (e) monitoring the biological state or the biological process in the cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or the tissue predominantly displaying at least one characteristic associated with a cardiac phenotype, thereby qualifying the effect of the treatment on the biological state or the biological process.

According to still further features in the described preferred embodiments, the treatment is effected by subjecting the cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or the tissue predominantly displaying at least one characteristic associated with a cardiac phenotype to an exposure to a compound or to an electrical treatment.

According to still further features in the described preferred embodiments, the method of qualifying the effect of a treatment on a biological state or a biological process further comprises isolating the cell aggregates from the cell population prior to step (b).

According to still further features in the described preferred embodiments, the method of qualifying the effect of a treatment on a biological state or a biological process further comprises isolating the embryoid bodies prior to step (c).

According to still further features in the described preferred embodiments, the method of qualifying the effect of a treatment on a biological state or a biological process further comprises screening and optionally isolating cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or tissue predominantly displaying at least one characteristic associated with a cardiac phenotype, the screening effected by at least one method selected from the group consisting of detection of mechanical contraction, detection of a cardiac specific structure, detection of a cardiac specific protein, detection of a cardiac specific RNA, detection of cardiac

specific electrical activity, and detection of cardiac specific changes in the intracellular concentration of a physiological ion.

According to still further features in the described preferred embodiments, the method of qualifying the effect of a treatment on a biological state or a biological process further comprises screening and optionally isolating cells substantially displaying proliferation or tissue substantially displaying proliferation.

According to still further features in the described preferred embodiments, the method of qualifying the effect of a treatment on a biological state or a biological process further comprises inducing the biological state or the biological process in the cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or the tissue predominantly displaying at least one characteristic associated with a cardiac phenotype.

According to still further features in the described preferred embodiments, the method of qualifying the effect of a treatment on a biological state or a biological process further comprises co-culturing the cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or the tissue predominantly displaying at least one characteristic associated with a cardiac phenotype with primary cardiac cells or primary cardiac tissue following step (c).

According to still further features in the described preferred embodiments, the method of qualifying the effect of a treatment on a biological state or a biological process further comprises transplanting the cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or the tissue predominantly displaying at least one characteristic associated with a cardiac phenotype into cardiac tissue of a recipient following step (c).

According to still further features in the described preferred embodiments, the inducing the biological state or the biological process is effected by treating the cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or the tissue predominantly displaying at least one

characteristic associated with a cardiac phenotype with a treatment selected from the group consisting of a treatment with a drug, a treatment with a physiological ion, and an electrical treatment.

According to still further features in the described preferred embodiments,  
5 the drug is selected from the group consisting of 1-heptanol, isoproterenol, carbamylcholine, forskolin, IBMX, atropine, tetrodotoxin, and diltiazem hydrochloride.

According to still further features in the described preferred embodiments,  
the physiological ion is selected from the group consisting of a potassium ion, a  
10 sodium ion, and a calcium ion.

According to still further features in the described preferred embodiments,  
the recipient is a swine.

According to still further features in the described preferred embodiments,  
the propagative electrical activity is characterized by slow conduction.

15 According to still further features in the described preferred embodiments,  
the biological state or the biological process is cardiac specific electrical activity  
and monitoring the biological state or the biological process is effected using a  
multielectrode array.

According to still further features in the described preferred embodiments,  
20 the multielectrode array comprises electrodes positioned 100  $\mu\text{m}$  or less apart.

According to still further features in the described preferred embodiments,  
the multielectrode array comprises at least 60 electrodes.

According to still further features in the described preferred embodiments,  
the multielectrode array measures electrical activity with a frequency o greater  
25 than a range selected from 1-25 kHz.

According to an additional aspect of the present invention there is  
provided a method of repairing cardiac tissue in a subject, the method  
comprising: (a) partially dispersing a confluent cultured population of human  
stem cells, thereby generating a cell population including cell aggregates; (b)  
30 subjecting the cell aggregates to culturing conditions suitable for generating

embryoid bodies; (c) subjecting the embryoid bodies to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of the embryoid bodies, the culturing conditions suitable for inducing cardiac lineage differentiation including adherence of the embryoid bodies to a surface, thereby generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or tissue predominantly displaying at least one characteristic associated with a cardiac phenotype; and (d) administering a therapeutically effective dose of the cells predominantly displaying at least one characteristic associated with a cardiac phenotype, and/or the tissue predominantly displaying at least one characteristic associated with a cardiac phenotype to the heart of the subject, thereby repairing cardiac tissue in the subject.

According to further features in preferred embodiments of the invention described below, the method of repairing cardiac tissue further comprises isolating the cell aggregates from the cell population prior to step (b).

According to still further features in the described preferred embodiments, the method of repairing cardiac tissue further comprises isolating the embryoid bodies prior to step (c).

According to still further features in the described preferred embodiments, the method of repairing cardiac tissue further comprises screening and optionally isolating cells predominantly displaying at least one characteristic associated with a cardiac phenotype or tissue predominantly displaying at least one characteristic associated with a cardiac phenotype, the screening effected by at least one method selected from the group consisting of detection of mechanical contraction, detection of a cardiac specific structure, detection of a cardiac specific protein, detection of a cardiac specific RNA, detection of cardiac specific electrical activity, and detection of cardiac specific changes in the intracellular concentration of a physiological ion.



According to still further features in the described preferred embodiments, the detection of cardiac specific electrical activity is effected using a microelectrode array.

According to still further features in the described preferred embodiments,  
5 the multielectrode array comprises electrodes positioned 100  $\mu\text{m}$  or less apart.

According to still further features in the described preferred embodiments, the multielectrode array comprises at least 60 electrodes.

According to still further features in the described preferred embodiments, the multielectrode array is configured to obtain data characterizing the cardiac  
10 specific electrical activity with a frequency greater than a range selected from 1-25 kHz.

According to still further features in the described preferred embodiments, the method of repairing cardiac tissue further comprises screening and optionally isolating cells substantially displaying proliferation or tissue substantially  
15 displaying proliferation.

According to still further features in the described preferred embodiments, the method of repairing cardiac tissue further comprises treating the subject with an immunosuppressive regimen, thereby promoting engraftment of the cells predominantly displaying at least one characteristic associated with a cardiac  
20 phenotype, or the tissue predominantly displaying at least one characteristic associated with a cardiac phenotype in the subject.

According to still further features in the described preferred embodiments, the method of repairing cardiac tissue further comprises inactivating or removing pathogenic cardiac cells or pathogenic cardiac tissue in the subject.

25 According to still further features in the described preferred embodiments, the administering is effected by injection of the cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or the tissue predominantly displaying at least one characteristic associated with a cardiac phenotype into the heart of the subject.

According to still further features in the described preferred embodiments, the human stem cells are embryonic stem cells.

According to still further features in the described preferred embodiments, the human stem cells are clonal.

5 According to still further features in the described preferred embodiments, the human stem cells are H9.2 cells.

According to still further features in the described preferred embodiments, the human stem cells are syngeneic with the subject.

10 According to still further features in the described preferred embodiments, the partially dispersing a confluent cultured population of human stem cells is effected via a non-trypsin based method.

According to still further features in the described preferred embodiments, the partially dispersing a confluent cultured population of human stem cells is effected via treatment with collagenase.

15 According to still further features in the described preferred embodiments, the culturing in step (b) is effected for a time period selected from the range of 1 to 20 days.

According to still further features in the described preferred embodiments, the culturing conditions in step (b) include inhibiting adherence of the cell  
20 aggregates to a surface.

According to still further features in the described preferred embodiments, the culturing conditions in step (b) include culture medium supplemented with serum.

25 According to still further features in the described preferred embodiments, the culturing in step (c) is effected for a time period selected from the range of 1–60 days.

According to still further features in the described preferred embodiments, the culturing in step (c) is effected in the presence of dimethyl sulfoxide.

According to still further features in the described preferred embodiments,

the culturing conditions in step (c) include exposing the embryoid bodies to a surface coated with gelatin.

According to still further features in the described preferred embodiments, the culturing conditions suitable for inducing cardiac lineage differentiation  
5 further include culture medium supplemented with serum.

According to yet an additional aspect of the present invention there is provided an *in-vitro* culture of isolated human cells which will display substantial proliferation for at least as long as a time period selected from the range of 1–35 days, and which will predominantly display at least one characteristic associated  
10 with a cardiac phenotype for at least as long as a time period selected from the range of 1–60 days.

According to still further features in the described preferred embodiments, the isolated human cells essentially have a genotype of H9.2 cells.

According to still an additional aspect of the present invention there is provided an *in-vitro* culture of an isolated human tissue which will display  
15 substantial proliferation for at least as long as a time period selected from the range of 1–35 days, and which will predominantly display at least one characteristic associated with a cardiac phenotype for at least as long as a time period selected from the range of 1–60 days.

20 According to still further features in the described preferred embodiments, the isolated human tissue essentially has a genotype of H9.2 cells.

According to still further features in the described preferred embodiments, the at least one characteristic associated with a cardiac phenotype is selected from the group consisting of cardiac specific mechanical contraction, a cardiac  
25 specific structure, expression of a cardiac specific RNA, expression of a cardiac specific protein, cardiac specific changes in the intracellular concentration of a physiological ion, and cardiac specific electrical activity.

According to still further features in the described preferred embodiments, the cardiac specific mechanical contraction is selected from the group consisting

of spontaneous mechanical contraction, rhythmic mechanical contraction, synchronous mechanical contraction, and propagative mechanical contraction.

According to still further features in the described preferred embodiments, the cardiac specific structure is selected from the group consisting of a sarcomere, a Z-band, an intercalated disc, a gap junction, a desmosome, a  
5 fibrillar bundle, a fibrillar bundle striation, and a myocytic syncytium.

According to still further features in the described preferred embodiments, the cardiac specific RNA encodes a protein selected from the group consisting of cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain,  $\alpha$ -actinin, cardiac  
10 troponin I, cardiac troponin T, GATA-4, Nkx2.5, MLC-2A, MLC-2V, atrial myosin light chain, ventricular myosin light chain, and connexin-43.

According to still further features in the described preferred embodiments, the cardiac specific protein is selected from the group consisting of cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain, atrial natriuretic peptide,  
15 cardiac troponin I, desmin and connexin-43.

According to still further features in the described preferred embodiments, the cardiac specific electrical activity is selected from the group consisting of spontaneous electrical activity, rhythmic electrical activity, synchronized electrical activity, and propagative electrical activity.

20 According to further features in the described preferred embodiments, the isolated human cells are cultured in contact with a multielectrode array configured for monitoring the cardiac specific electrical activity.

According to further features in the described preferred embodiments, the isolated human tissue is cultured in contact with a multielectrode array  
25 configured for monitoring the cardiac specific electrical activity.

According to still further features in the described preferred embodiments, the subject is a human or a nonhuman mammal.

According to still further features in described preferred embodiments, the subject has a cardiac disorder characterized by cardiac arrhythmia, and the  
30 administering is effected by intra-myocardial injection of the cells predominantly

displaying at least one characteristic associated with a cardiac phenotype, or tissue predominantly displaying at least one characteristic associated with a cardiac phenotype, thereby treating the disorder characterized by cardiac arrhythmia.

5 According to still further features in described preferred embodiments, the subject has a cardiac disorder characterized by myocardial ischemia, and the administering is effected by intra-myocardial injection of the cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or tissue predominantly displaying at least one characteristic associated with a  
10 cardiac phenotype, thereby treating the disorder characterized by myocardial ischemia.

The present invention successfully addresses the shortcomings of the presently known configurations by providing a method of using *in-vitro* culture of human differentiable cells to generate highly differentiated, highly functional  
15 cardiac cells and tissues.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the  
20 present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

25

#### BRIEF DESCRIPTION OF THE DRAWINGS

The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for  
30 purposes of illustrative discussion of the preferred embodiments of the present



invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a  
5 fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.

In the drawings:

FIG. 1a is a schematic diagram depicting the three stages of differentiation  
10 of human embryonic stem cells into cells and tissues displaying cardiomyocytic characteristics. Initially, the embryonic stem cell colonies are grown on top of the mouse embryonic feeder (MEF) feeder layer (left). To induce differentiation, cells are transferred to suspension, where they aggregate to form embryoid bodies (middle). Following 10 days in suspension, embryoid bodies are plated  
15 on gelatin-coated culture dishes, where they are examined for the appearance of spontaneous contractions (right).

FIGs. 1b-d are photomicrographs depicting cells during the three stages of differentiation of human embryonic stem cells into cells displaying cardiomyocytic characteristics: embryonic stem cell colony (Figure 1b),  
20 embryoid bodies in suspension (Figure 1c), and a contracting area in the outgrowth on an embryoid body (Figure 1d).

FIG. 2 is a data plot depicting cumulative percentage of embryoid bodies containing spontaneously contracting areas as a function of the number of days postplating of the embryoid body. Embryoid bodies were found to display  
25 plateau levels of contraction for at least 60 days, the longest time period studied (not shown in Figure).

FIGs. 3a-e are transmission electron micrographs depicting cardiomyocyte specific ultrastructural characteristics of embryonic stem cell-derived cardiomyocytic cells. Figure 3a depicts a section of a beating embryoid body  
30 10 days postplating. Relatively unorganized myofibrillar bundles can be seen in

some myocytes. Figure 3b depicts a cell 27 days postplating displaying a more mature sarcomeric organization. Figure 3c depicts different cells from the same embryoid body as in Figure 3b demonstrating more organized sarcomeres and Z-bands (arrow). Figures 3d and 3e are high-power electron micrographs showing the presence of a gap junction (arrow) and desmosomes (arrow), respectively.

FIGs. 4a-f are fluorescence photomicrographs depicting expression of cardiac muscle specific, but not skeletal muscle specific proteins in embryonic stem cell-derived cardiomyocytic cells. Figure 4a depicts immunostaining of dispersed cells from a beating embryoid body (day 16 postplating) with anti cardiac  $\alpha/\beta$ -myosin heavy chain mAbs. Several cells stained positively ( $\times 40$  magnification). Figure 4b depicts immunostaining with anti cardiac  $\alpha/\beta$ -myosin heavy chain mAbs of dispersed cells from a beating embryoid body of a cardiomyocyte (day 16 postplating) at a more developed stage ( $\times 63$  magnification). Note the appearance of early striation pattern (arrow). Figure 4c depicts positive staining with anti sarcomeric  $\alpha$ -actinin mAbs (day 17 postplating;  $\times 63$  magnification). Figure 4d depicts positive staining with cTnI mAbs (day 30 postplating;  $\times 63$  magnification). Figure 4e depicts positive staining with anti desmin mAbs (day 18 postplating;  $\times 63$  magnification). Figure 4f depicts positive staining with anti atrial natriuretic peptide antibody (day 16 postplating  $\times 63$  magnification).

FIG. 5 is a series of fluorescence photographs depicting expression of cardiac specific genes in the contracting embryoid bodies. RNA samples from undifferentiated embryonic stem cells (ES) and contracting embryoid bodies (C-EBs) were analyzed by RT-PCR for the expression of cardiac-specific markers: cardiac troponin I (cTnI), cardiac troponin T (cTnT), GATA-4, human atrial natriuretic peptide (hANP), MLC-2A, MLC-2V, Nkx2.5, and  $\alpha$ -myosin heavy chain ( $\alpha$ -MHC). Octamer-binding protein 4 (Oct-4) is an embryonic stem cell marker. GAPDH served as internal standard. -RT indicates no cDNA.

FIGs. 6a-b are data plots depicting a typical calcium transient (Figure 6a) and a continuous recording of calcium transients (Figure 6b) in cultured human

embryonic stem cell-derived cardiomyocytic cells as determined by fura-2 fluorescence.  $T_p$  – time to peak,  $T_T$  – total transient time, and  $T_{1/2}$  – time to half-peak relaxation, ms – milliseconds.

FIG. 6c is a data plot depicting typical extracellular electrophysiological recordings from different areas of the embryoid body. Note the presence of a sharp and slow component. ms – milliseconds.

FIG. 7 is a photograph depicting a microelectrode array (MEA) plate, which consists of 60 electrodes spaced 100  $\mu$ m apart.

FIGs. 8a-c are fluorescence photomicrographs depicting immunostaining of contracting areas within an embryoid body. Figure 8a depicts immunostaining using anti cTnI antibody (green), Figure 8b depicts representative confocal images of the Cx43 immunofluorescent signal showing the spatial distribution of gap junctions, and Figure 8c depicts co-staining of a contracting embryoid body with anti cTnI (green) and anti Cx43 (red) antibodies.

FIGs. 9a-d depict multielectrode electrophysiological analysis of a unifocal contracting embryoid body. Figure 9a is a photomicrograph depicting a contracting embryoid body plated on a microelectrode array plate. Figure 9b is a set of data plots depicting typical extracellular recordings from all 60 electrodes of the microelectrode array. Figure 9c is a data plot depicting a high-resolution activation map generated from local activation times (LATs) measured at each electrode. Note that, in this example, activation propagates from the lower left side of the microelectrode array (earliest site – red) towards the right upper area (latest activation site – blue). A conduction velocity vectorial map, represented by arrows whose sizes correlate with the local conduction velocity, is superimposed on the activation map. Figure 9d is a histogram depicting the resulting activation time histogram of the activation map depicting in Figure 9c, characterized by a single cluster of activation times, which is continuous from early to late LATs, typical of an embryoid body with a broad conducting area.

FIGs. 10a-c depict multielectrode electrophysiological analysis of an embryoid body with two contracting areas connected through a narrow

conducting zone. Figure 10a is fluorescence photomicrograph depicting immunostaining of the embryoid body with anti cTnI antibody (green). Note the narrow connecting region between the two contracting areas located between the two gray markers. Figure 10b is an activation map of the contracting areas showing the presence of early activated sites (red and yellow) in the top portion of the microelectrode array and late activated sites (blue and dark blue) in the lower part, with slow conduction between these two zones. Black areas indicate electrodes in which no electrical activity was recorded. The gray markers allow comparison between this activation map and the micrograph in Figure 10a since they mark the same electrodes in both figures. Note the spatial correlation between the narrow connecting region and the area of slow conduction. Figure 10c is a histogram depicting early and late activation times clusters with a paucity of intermediate values.

FIGs. 11a-d depict activation maps of the same embryoid body depicting the slowing of conduction induced by gradual elevation of extracellular potassium concentration. Note the significant slowing of conduction that was manifested by an increase in total activation time from a baseline value of 25 milliseconds (5.3 mM, Figure 11a) to values of 40, 70, and 120 milliseconds at extracellular potassium concentrations of 10, 15, and 20 mM (Figures 11b-d, respectively).

FIGs. 12a-b depict activation maps of the same embryoid body during baseline (Figure 12a) and following application of 10  $\mu$ M TTX (Figure 12b). Note the increase in total microelectrode array activation time from a baseline value of 15 milliseconds to a value of 35 milliseconds in this example.

FIGs. 13a-b depict activation maps of the same embryoid body during baseline (Figure 13a) and following application of 0.3 mM of 1-heptanol (Figure 13b). Reduction of cell-to-cell coupling by 1-heptanol resulted in slowing of conduction, as manifested by an increase of total activation time from a baseline value of 15 to a value of 32 milliseconds.

FIGs. 14a-b are a photomicrograph of a structurally inhomogeneous

embryoid body and its activation map, respectively, depicting the effect of structural inhomogeneities (Figure 14a) on microconduction (Figure 14b). Note that the presence of noncontracting tissue (identified by the set of 3 parallel arrows) resulted in alteration of the propagation pathway. The resulting activation wavefront curvature (identified by the angled arrow) was associated with significant slowing of conduction, as can be appreciated by the prolonged total microelectrode array activation time.

FIGs. 15a-b depict a microelectrode array generated high-resolution activation map (Figure 15a) and positive chronotropic responses following addition of 10  $\mu$ M isoproterenol (Figure 15b, indicated by arrow) of spontaneously contracting cultured human embryonic stem cell-derived cardiomyocytic cells used to generate hybrid rat ventricular myocyte-human embryonic stem cell-derived cardiomyocyte co-cultures.

FIG. 16a depicts a phase-contrast photomicrograph of a hybrid human embryonic stem cell-derived cardiomyocyte-rat primary cardiomyocyte culture grown on a microelectrode array plate showing the cultured human embryonic stem cell-derived cardiomyocytic cells in the upper part as a white cluster.

FIGs. 16b-c depict an activation map of spontaneous activity showing the activation origin (red) in the rat tissue propagating to the rest of the co-culture (Figure 16b), and simultaneous recordings from the human embryonic stem cell-derived (upper trace) and rat (lower trace) tissues (Figure 16c). The activation map corresponds to the micrograph shown in Figure 16a and the human and rat traces were generated from the electrodes indicated by red and green circles, respectively, in Figure 16a.

FIGs. 16d-e depict an activation map (Figure 16c) and simultaneous recordings (Figure 16d) from the rat (lower trace) and human (upper trace) tissues during pacing from an electrode positioned in the rat tissue in the lower left corner area of the culture. The activation map corresponds to the micrograph shown in Figure 16a and the human and rat traces were generated



from the electrodes indicated by red and green circles, respectively, in Figure 16a.

FIGs. 16f-g depict an activation map (Figure 16f) and simultaneous recordings (Figure 16g) from the rat (lower trace) and human (upper trace) tissues during pacing from an electrode positioned in the human tissue in the top, left-of-center area of the culture. The activation map corresponds to the micrograph shown in Figure 16a and the human and rat traces were generated from the electrodes indicated by red and green circles, respectively, in Figure 16a.

FIG. 16h is a data plot depicting optical recordings of the mechanical activity in the contracting embryoid body (top) synchronous with the electrical activity in the human (middle) and rat (bottom) tissues.

FIG. 16i are histograms depicting the fixed cycle-lengths ratios between the rat and human tissues. The narrow peak at a ratio of 1 represents synchronous activity and was found during long-term recordings in all cultures at baseline (left) and following isoproterenol administration (right).

FIGs. 17a-b are photomicrographs depicting formation of abundant gap junctions between cultured human embryonic stem cell-derived cardiomyocytic cells and primary ventricular cardiomyocytes. Figure 17a is a representative high magnification confocal fluorescence photomicrograph depicting the spatial distribution of gap junction (positive punctate Cx43 staining, green) in the co-cultures. The human embryonic stem cell-derived cardiomyocytic cells were identified via anti human HLA antibody (red cells). Note the presence of gap junctions between the cultured human embryonic stem cell-derived cardiomyocytic cells (arrow head) and at the interphase between the cultured human embryonic stem cell-derived cardiomyocytic cells and the primary ventricular cardiomyocytes (arrow). Figure 17b is a confocal photomicrograph demonstrating transfer of lucifer yellow from the primary ventricular myocytes to the cultured human embryonic stem cell-derived cardiomyocytic cells (arrow).

FIGs. 18a-c depict typical body surface recordings (leads I, II, III) of nodal escape rhythm, ventricular rhythm, and new ventricular rhythm originating from the posterolateral area of the left ventricle (Figures 18a-c, respectively) following the creation of complete atrioventricular block showing complete  
5 atrioventricular dissociation.

FIGs. 19a-f depict electroanatomical mapping of the nodal escape rhythm (Figures 19a and 19c) and the new ventricular rhythm following cell transplantation (Figures 19b, 19d and 19f). Maps are shown from an anteroposterior (Figures 19a-b), left lateral (Figures 19c-d), and posteroanterior  
10 (Figure 19f) views. Note that the earliest activation during nodal rhythm (red area) originates from the superior septum and propagates to the rest of the ventricle, activating the lateral wall last (blue-purple area). In contrast, earliest activation during mapping of the new rhythm originated in the posterolateral wall with the septum being activated last. In order to correlate the electroanatomical  
15 map (Figure 19f) with pathology (Figure 19e), the earliest activation was identified (Figure 19f, arrow), the catheter was navigated 2 cm from this position and a radiofrequency ablation was performed (Figure 19f, arrow head). Note the spatial correlation in pathology with the ablation site (Figure 19e, marked by the pink needle) being exactly 2 cm away from the suture, indicating the site of cell  
20 injection.

FIGs. 20a-d are photomicrographs of histological analyses depicting the presence of engrafted cultured human embryonic stem cell-derived cardiomyocytic cells in recipient cardiac tissue. Figure 20a depicts hematoxylin and eosin (H&E) staining ( $\times 4$  magnification) of transplanted cells within the  
25 recipient myocardial wall. Figure 20b depicts the presence of transplanted cells within the left ventricular myocardium via fluorescence from the vital lipophilic tracer CM-DiI (red). Figures 20c-d are confocal fluorescence photomicrographs of a section taken from the injection area demonstrating the presence of engrafted cells via staining with anti cardiac troponin I (cTnI) immunostaining (Figure 20c, green), and via CM-DiI fluorescence (Figure 20d, red).  
30

FIGs. 21a-h are photomicrographs depicting proliferative capacity in cardiomyocytic cells and tissue generated by *in-vitro* culture, as determined via  $^3\text{[H]}$ -thymidine uptake and autoradiography. Shown is  $^3\text{[H]}$ -thymidine uptake in undifferentiated stem cells (Figures 21a-b) and in cardiomyocytic cells and tissues (identified by positive staining with anti- $\alpha$ -actinin antibodies) at 10 days postplating (Figures 21c-d), 30 days postplating (Figures 21e-f) and 50 days postplating (Figures 21g-h). Figures 21a, 21c, 21e and 21g – low magnification fields; Figures 21b, 21d, 21f and 21h – high magnification fields.

## 10 DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is of methods of generating human cells and tissues predominantly displaying at least one characteristic associated with a cardiac phenotype, and of methods of using such cells and tissues to repair cardiac tissues, to qualify the effects of treatments on biological states and processes of cardiac cells and cardiac tissues, and to characterize biological states and processes of cardiac cells and cardiac tissues.

Specifically, the present invention can be used to generate cultured human cardiomyocytic cells and tissues displaying a broader range of human cardiac specific structures and functions than prior art cultured differentiable cell-derived cells and tissues, displaying such human specific and cardiac specific structures and functions for longer time periods than prior art cultured differentiable cell-derived cells and tissues, and displaying significant proliferative capacity. As such, the present invention can be used to generate human cardiomyocytic cells and tissues which can be used to treat human cardiac disorders with far greater efficacy than prior art cultured differentiable cell-derived cells and tissues, to test the therapeutic and toxic effects of treatments, such as pharmacological and electrical treatments, on human cardiac cells and tissues more efficiently and accurately than with prior art cultured differentiable cell-derived cells and tissues, to characterize cardiac specific gene expression, and to optimally model

human cardiomyogenesis and human cardiac physiology relative to prior art cultured differentiable cell-derived cells and tissues.

The principles and operation of the present invention may be better understood with reference to the accompanying descriptions and examples.

5 Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of the components set forth in the following description or exemplified in the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to  
10 be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.

Death or damage of cardiomyocytes or myocardium as a result of diseases associated with cardiac cell or tissue necrosis, such as ischemic cardiac disease oftentimes leads to mortality or disability since adult cardiomyocytes are  
15 incapable of proliferating *in-vivo*.

Such inability of adult cardiomyocytes to proliferate represents a major stumbling block to approaches attempting to utilize *in-vitro* culture of adult cardiomyocytes to generate cardiomyocytic cells and tissues suitable for treating cardiac disorders, such as myocardial infarction, for testing the effects, such as  
20 the therapeutic and toxic effects of treatments, such as pharmacological and electrical treatments, on human cardiac cells and tissues, for characterizing cardiac specific gene expression, and for modeling aspects of human cardiac biology, such as human cardiac development and human cardiophysiology.

Various prior art approaches have attempted to use *in-vitro* culture of  
25 differentiable cells to generate cardiomyocytic cells and tissues suitable for such applications.

However, all prior art approaches have failed to provide an adequate solution for utilizing *in-vitro* culture of differentiable cells to generate cardiac cells and tissues suitable for treating human cardiac disorders, and for testing the

pharmacological effect and toxicity of compounds on human cardiac cells and tissues.

While experimenting with cultured human embryonic stem cells, the present inventors unexpectedly uncovered that culturing human stem cells according to the method of the present invention could be used to generate cardiomyocytic cells and tissues displaying far greater cardiac specific differentiation and functionality than any prior art cultured differentiable cell-derived cells and tissues. It was further uncovered that the cardiomyocytic cells and tissues generated according to the method of the present invention displayed, for the first time by cultured differentiable cell-derived cells and tissues, a broad spectrum of human specific and cardiac specific responses, such as physiological responses, to treatments, such as pharmacological and electrical treatments. It was yet further uncovered, also for the first time by cultured differentiable cell-derived cells and tissues, that the cardiomyocytic cells and tissues of the present invention displayed human specific functional integration with primary cardiomyocytes and myocardium *in-vitro* and *in-vivo*, respectively. It was still yet further uncovered that the cardiomyocytic cells and tissues of the present invention display significant proliferative capacity.

Thus, the cells and tissues of the present invention can be used to treat human cardiac disorders, to test the effects, such as the therapeutic and toxic effects, of treatments, such as pharmacological and electrical treatments, on human cardiac cells and tissues, to characterize cardiac specific gene expression, and to model aspects of cardiac biology, such as human cardiac development and human cardiac electrophysiology, all of which optimally relative to methods employing prior art cultured differentiable cell-derived cells and tissues.

As used herein, "differentiable" cells are cells that can differentiate. Differentiable cells include, but are not limited to, non-differentiated cells, stem cells, totipotent cells, partially differentiated cells, progenitor cells, precursor cells, pluripotent cells, de-differentiated cells, and the like.



Thus, according to one aspect of the present invention, there is provided a method of generating cardiac cells and tissues predominantly displaying at least one characteristic associated with a cardiac phenotype.

As described in detail in Example 1 of the Examples section below, the method of generating the cardiac cells and tissues of the present invention is effected by partially dispersing a confluent cultured population of human stem cells into cell aggregates, preferably containing two or more cells, most preferably containing 3–20 cells.

As used herein, the phrase “cells and tissues of the present invention” refers to the cells and tissues predominantly displaying at least one characteristic associated with a cardiac phenotype of the present invention.

As used herein, a “confluent” population of cultured cells is a population of cultured cells which are adhesively interconnected, and which may or may not cover the entire available growth surface of the culture recipient in which they are cultured.

The stem cells used to generate the cells and tissues of the present invention are preferably embryonic stem cells which are grown as established cell lines, such as, for example, those described in U.S. patent 5,843,780 to J. Thomson, or by Thomson J. *et al.*, 1998. Science 282:1145-1147. In order to ensure optimal results, single-cell clone derived embryonic stem cell lines are established and cultured according to the method of the present invention. This facilitates selection of optimal cell lines for generating the cells and tissues of the present invention, as described in Example 1 of the Examples section below.

Preferably, the human single cell derived cell line H9.2, derived from cell line H9 (Amit, M. *et al.*, 2000. Dev Biol. 227:271) is employed to generate the cells and tissues of the present invention, as described in the Examples section which follows. The use of human cell lines, such as H9.2 according to the present invention, is greatly advantageous over prior art methods since it uniquely enables the generation of highly differentiated, highly functional, substantially proliferating human cardiomyocytic cells and tissues *in-vitro*.

Various techniques, such as physical or, more preferably, chemical techniques can be employed for partially dispersing a confluent population of cells. Confluent cells are preferably partially dispersed enzymatically, preferably via a non-trypsin based method, preferably using collagenase, preferably collagenase IV. Alternately, enzymes such as dispase can be employed. Application of shear flow to enzymatically treated cells may be employed to obtain a desired degree of dispersion.

Following partial dispersion of confluent stem cells, cell aggregates are subjected to culturing conditions suitable for generating embryoid bodies, as described in further detail in Example 1 of the Examples section which follows. Embryoid bodies are easily recognized by the ordinary artisan as being coalesced embryonic stem cells displaying a characteristic structure and morphology in culture, as furthermore abundantly taught by the literature of the art. Optionally, cell aggregates are isolated, for example via microcapillary suction under a stereoscope prior to being subjected to culturing conditions suitable for generating embryoid bodies. The typical appearance of embryoid body morphology, according to the present invention, is illustrated in Figure 1c of the Examples section below.

Culturing conditions suitable for generating embryoid bodies from cell aggregates preferably comprise inhibiting adherence of the cell aggregates to a surface, and preferably further comprise supplementing the culturing medium with serum, as described further in Example 1 of the Examples section which follows.

Inhibiting adherence of cells to a surface, such as the lower surface of a culturing recipient, is optimally effected using a culturing recipient having non-coated cell-contacting surfaces, such as, for example, non-tissue culture coated plastic bacteriology culture dishes, as described in Example 1 of the Example section below. Preventing adherence of cells to a surface of a culturing recipient can be further enhanced by culturing the cells with shaking.

Culturing of cell aggregates to induce generation of embryoid bodies is preferably effected by culturing embryoid bodies at a cell-to-surface density ranging from about  $5 \times 10^4$  to  $1 \times 10^6$  cells/cm<sup>2</sup>, more preferably ranging from about 100,000 to about 500,000 cells/cm<sup>2</sup>, and most preferably at a cell density of about 200,000 cells/cm<sup>2</sup>. Formation of embryoid bodies can be enhanced by culturing cell aggregates under conditions allowing cell-cell contacts therebetween.

Culturing cell aggregates to generate embryoid bodies can be effected, for example, by culturing about five million cells in a volume of about 7 ml of culture medium, for example in a circular 58 millimeter diameter Petri dish, as described in Example 1 of the Examples section which follows.

Culturing of cell aggregates for generation of embryoid bodies is preferably effected for a time period ranging from about 1 day to 20 days, more preferably ranging from about 5 days to 20 days, more preferably ranging from about 5 days to 15 days, and most preferably for about 7 days to 10 days, as described in Example 1 of the Examples section below.

Prior art approaches have taught either trypsinization to disperse confluent stem cells, or the use of a hanging drop culture phase during the process of generating embryoid bodies from dispersed cells, or both. Such approaches are not adequate for generating the human cells and tissues of the present invention. For example, trypsinization of confluent human stem cells was found by the present inventors to lead to widespread karyotypic abnormalities in cells and tissues derived therefrom.

Following generation thereof, embryoid bodies are preferably subjected to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of the embryoid bodies. Optionally, embryoid bodies are isolated, for example via microcapillary suction under a stereoscope prior to being subjected to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of the embryoid bodies. A typical embryoid body with cells having undergone cardiac lineage differentiation via

the method of the present invention is shown in Figure 1d of the Examples section which follows.

As used herein, cells or tissues having undergone "cardiac lineage differentiation" are cells or tissues predominantly displaying at least one  
5 characteristic associated with a cardiac phenotype, as further described hereinbelow.

Culturing conditions suitable for inducing cardiac lineage differentiation preferably promote adherence of embryoid bodies to a surface, preferably the lower, cell-contacting surface of the culture recipient, and preferably further  
10 include the use of culture medium supplemented with serum.

Serum supplementation preferably comprises addition of fetal bovine serum to a volume/volume (v/v) concentration of at least about 1 %, more preferably at least about 5 %, more preferably at least about 10 %, more preferably at least about 15 %, and most preferably at least about 20 %.

15 To promote adherence of embryoid bodies to a surface, such as the lower surface of a culture recipient, the surface is preferably coated with gelatin. Coating a surface with gelatin is preferably effected by exposing the surface to a solution containing gelatin, and incubating the surface in the presence of the solution, for example, for about sixteen hours at about 4 °C, or for about thirty  
20 minutes to two hours at about 37 °C. Preferably, a solution containing about 0.1 % gelatin is used, as described in Example 1 of the Examples section which follows.

Alternately, adherence of embryoid bodies to a surface can be promoted, for example, by culturing the embryoid bodies in a recipient having cell-  
25 contacting surfaces coated with an extracellular matrix (ECM) component, such as fibronectin, or with a mixture of extracellular matrix components, such as Matrigel™, or by culturing the embryoid bodies in tissue culture coated tissue culture dishes, such as Falcon™ tissue culture-coated culture dishes.

Culturing embryoid bodies to induce cardiac lineage differentiation in at  
30 least a portion of the cells of the embryoid bodies is preferably effected for a

duration of at least: 1 day, more preferably 2 days, more preferably 3 days, more preferably 4 days, more preferably 5 days, more preferably 6 days, more preferably 7 days, more preferably 8 days, more preferably 9 days, more preferably 10 days, more preferably 11 days, more preferably 12 days, more preferably 13 days, more preferably 14 days, more preferably 15 days, more preferably 16 days, more preferably 17 days, more preferably 18 days, more preferably 19 days, more preferably 20 days, more preferably 21 days, more preferably 22 days, more preferably 23 days, more preferably 24 days, more preferably 25 days, more preferably 26 days, more preferably 27 days, more preferably 28 days, more preferably 29 days, more preferably 30 days, more preferably 31 days, more preferably 32 days, more preferably 33 days, more preferably 34 days, more preferably 35 days, more preferably 36 days, more preferably 37 days, more preferably 38 days, more preferably 39 days, more preferably 40 days, more preferably 41 days, more preferably 42 days, more preferably 43 days, more preferably 44 days, more preferably 45 days, more preferably 46 days, more preferably 47 days, more preferably 48 days, more preferably 49 days, more preferably 50 days, more preferably 51 days, more preferably 52 days, more preferably 53 days, more preferably 54 days, more preferably 55 days, more preferably 56 days, more preferably 57 days, more preferably 58 days, more preferably 59 days, and most preferably 60 days.

The time period during which embryoid bodies are cultured can be varied according to the cardiac differentiation features which are desired. For example, as described in Figure 3 of the Examples section below, culturing embryoid bodies for a time period ranging from 10 days to 27 days can be used to generate cells displaying increasingly mature myofibrillar organization. As described in Example 4 of the Examples section below, culturing embryoid bodies for 7–20 days can be used to generate optimally proliferating cardiomyocytic cells and tissues. In general, as described in Example 4 of the following Examples section, the shorter the duration of embryoid body culture, the greater the proliferative capacity of the cardiomyocytic cells and tissues generated.



Culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of the embryoid bodies preferably comprise supplementing the culture medium with dimethyl sulfoxide (DMSO), preferably 0.75 percent (v/v) dimethyl sulfoxide. As described in the Examples section  
5 which follows, this can be used to increase the percentage of embryoid bodies with cells displaying cardiac lineage differentiation by about 20 %.

As described in Example 1 of the Examples section hereinbelow it was uncovered by the present inventors that not all embryoid bodies cultured under conditions suitable for inducing cardiac lineage differentiation only contain cells  
10 displaying cardiac lineage differentiation. Thus, the method according to this aspect of the present invention preferably further comprises screening and identifying cells and tissues displaying cardiac lineage differentiation within the cultured embryoid bodies.

According to the method of the present invention, screening is performed  
15 by a method enabling detection of at least one characteristic associated with a cardiac phenotype, as described hereinbelow, for example via detection of cardiac specific mechanical contraction, detection of cardiac specific structures, detection of cardiac specific proteins, detection of cardiac specific RNAs, detection of cardiac specific electrical activity, and detection of cardiac specific  
20 changes in the intracellular concentration of a physiological ion.

Preferably, screening the cells and tissues of the present invention comprises detection of mechanical contraction. Cardiac specific mechanical contraction can often be identified in outgrowths of embryoid bodies such as that highlighted in Figure 1d of the Examples section below.

25 Various techniques can be used to detect each of cardiac specific mechanical contraction, cardiac specific structures, cardiac specific proteins, cardiac specific RNAs, cardiac specific electrical activity, and cardiac specific changes in the intracellular concentration of a physiological ion.

Detection of cardiac specific mechanical contraction is preferably effected  
30 visually using an optical microscope. Alternately, such detection can be effected

and recorded using a microscope equipped with a suitable automated motion detection system using, for example, a photodiode, as described in Example 3, and as demonstrated in Figure 16h of the Examples section below.

Detection of cardiac specific structures is preferably performed via light microscopy, fluorescence affinity labelling and fluorescence microscopy, or electron microscopy, depending on the type of structure whose detection is desired. Light microscopy can be used to detect various cardiac specific structures, such as mononuclear cells, about 10–30  $\mu\text{m}$  in diameter, with round or rod-shaped morphology characteristic of immature cardiomyocytes, as described in Example 1 of the Examples section which follows. For resolution of details, phase contrast microscopy may be employed, as described in the Examples section.

To detect cardiac specific structures via electron microscopy, the transmission electron microscopy protocol described in detail in Example 1 of the following Examples section is preferably employed. Alternately, numerous suitable protocols which are available in the literature can also be utilized. Electron microscopy can be used to detect various cardiac specific structures, such as sarcomeres, Z-bands, intercalated discs, gap junctions, desmosomes, fibrillar bundles, fibrillar bundle striations, and myocytic syncytia, as demonstrated in Figure 3 of the Examples section which follows.

To detect cardiac specific structures via fluorescence affinity labelling and fluorescence microscopy, such structures may be fluorescently labelled via a molecule, commonly an antibody, which specifically binds such a structure, and which is either directly or indirectly conjugated to a fluorophore. Automated quantitation of such structures can be performed using appropriate detection and computation systems, for example, as described and as demonstrated in the Examples section below. When using an antibody as an affinity labelling reagent, this technique may be referred to as immunocytochemistry or immunohistochemistry. Using the appropriate affinity labelling reagents and fluorophores, fluorescence affinity labelling and fluorescence microscopy can be

used to detect various cardiac specific structures, including, but not limited to, sarcomeres, gap junctions, fibrillar bundles, fibrillar bundle striations, and myocytic syncytia, as is described and illustrated in the Examples section which follows.

5        Detection of cardiac specific proteins is preferably effected via fluorescence affinity labelling and fluorescence microscopy, as described hereinabove for detection of a cardiac specific structure. Alternately, techniques such as Western immunoblotting or hybridization microarrays ("protein chips") may be employed. As is illustrated in the Examples section below, fluorescence  
10        affinity labelling and fluorescence microscopy can be used to detect cardiac specific proteins, such as cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain, atrial natriuretic peptide, cardiac troponin I, desmin and connexin-43.

      Detection of cardiac specific RNAs is preferably effected using RT-PCR, for example using the protocol and primers described Example 1 of the Examples  
15        section below. Alternately, other commonly used methods, such as hybridization microarray ("RNA chip") or Northern blotting, may be employed. RT-PCR can be used to detect cardiac specific RNAs encoding essentially any protein, including cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain,  $\alpha$ -actinin, cardiac troponin I, cardiac troponin T, GATA-4, Nkx2.5, MLC-2A,  
20        MLC-2V, atrial myosin light chain, ventricular myosin light chain, and connexin-43, as is demonstrated in Figure 5 of the Examples section.

      Detection of cardiac specific changes in the intracellular concentration of a physiological ion, such as calcium, is preferably effected using assays based on fluorescent ion binding dyes such as the fura-2 calcium binding dye (for  
25        example, refer to Brixius, K. *et al.*, 1997. J Appl Physiol. 83:652). Such assays can be advantageously used to detect changes in the intracellular concentration of calcium ions, such as calcium transients, as is illustrated in Figures 6a-b of the Examples section below.

      Detection of cardiac specific electrical activity of the cells and tissues of  
30        the present invention is preferably effected by monitoring the electrical activity

thereof via a multielectrode array. Suitable multielectrode arrays may be obtained from Multi Channel Systems, Reutlingen, Germany, and are preferably employed as described in the following Examples section.

Preferably, the multielectrode array utilized by the present invention is a two-dimensional orthogonal array which includes 60 or more electrodes positioned 100  $\mu\text{m}$  or less apart.

Preferably, the multielectrode array is configured to obtain data characterizing cardiac specific electrical activity with a frequency greater than a range selected from 1-25 kHz.

To detect cardiac specific electrical activity in the cells and tissues of the present invention, the latter can be advantageously cultured, under conditions suitable for inducing cardiac differentiation directly on a multielectrode array, thereby conveniently enabling monitoring the electrical activity such cells and tissues. Regions of embryoid bodies displaying cardiac differentiation, preferably in the form of cardiac specific mechanical contraction, can be advantageously microdissected from embryoid bodies and cultured on microelectrode arrays, as described in Example 1 of the Examples section, below. Such direct culturing on a multielectrode array advantageously enables the monitoring of long-term electrical activity of the cells and tissues of the present invention, as described in the Examples section which follows.

Monitoring electrical activity in the cells and tissues of the present invention can be used to provide many different types of important and novel information regarding electrical activity of cells and tissues of the present invention. For example, such monitoring can be used to monitor electrical activity individually at each electrode, or more advantageously, such monitoring can be used to generate electrical activity propagation maps, also termed herein "activation maps", depicting electrical activity as a function of local activation time at each electrode, for example in the form of a color-coded gradient. Such activation maps can be used to depict conduction velocity and conduction directionality of propagative electrical activity, preferably in the form of

conduction velocity vectors, of electrical activity propagation over an area of the microelectrode array, as is illustrated, for example in Figure 9 of the following Examples section.

According to a preferred embodiment of the present invention, the present method further comprises isolating the cells and tissues of the present invention from embryoid bodies. Such isolation is preferably performed by mechanical dissection of cells and tissues displaying the desired characteristic with a pulled-glass micropipette or microscalpel, as described in the Examples section which follows. Alternately, cells and tissues displaying a cell surface molecule which can be specifically bound by a reagent may be isolated by fluorescence-activated cell sorting (FACS).

Since the proliferative capacity of the cells and tissues of the present invention may be essential to a given use thereof, for example, to repair cardiac tissue, or to test the effects of a treatment on growth or differentiation of cardiac cells and tissues, the method according to this aspect of the present invention may advantageously further comprise screening and optionally isolating cells and tissues substantially displaying proliferation. Determining the proliferative capacity of cells can be performed by numerous standard techniques. Preferably, determination of proliferation is effected via  $^3\text{[H]}$ -thymidine uptake assay and autoradiographic detection of such uptake, as described in Example 4 of the following Examples section and illustrated in Figures 21c-f. Alternately, colorimetric assays employing metabolic dyes such as XTT, or direct cell counting may be employed to ascertain proliferative capacity.

Thus, the method of the present invention is unique over prior art methods in that it enables generation of proliferating cells and tissues predominantly displaying characteristics associated with a cardiac phenotype by *in-vitro* culture of differentiable cells. Furthermore, since the method of the present invention can be used to generate such cells and tissues *in-vitro*, the method of the present invention possesses the unique and extremely useful capacity to generate essentially unlimited numbers of such cells and tissues.



As is illustrated in the Examples section which follows, the cells and tissues generated using the methodology of the present invention display characteristics associated with a cardiac phenotype including, but not limited to, cardiac specific mechanical contraction, cardiac specific structures, expression of cardiac specific RNAs, expression of cardiac specific proteins, cardiac specific changes in the intracellular concentration of a physiological ion, and cardiac specific electrical activity, as further described hereinbelow.

Preferably the cardiac phenotype is a cardiomyocytic phenotype. As evidenced by the characteristic spectrum of structures and functions displayed by the cells and tissues of the present invention described below and in the Examples section below, the cells and tissues of the present invention clearly display a highly functional, highly differentiated cardiomyocytic phenotype.

Preferably, the cells and tissues of the present invention display cardiac specific mechanical contraction, more preferably in combination with at least some, and most preferably in combination with at least all of the following characteristics associated with a cardiac phenotype: cardiac specific structures, expression of cardiac specific RNAs, expression of cardiac specific proteins, cardiac specific changes in the intracellular concentration of a physiological ion, and cardiac specific electrical activity.

The cells and tissues of the present invention display types of cardiac specific mechanical contraction including, but not limited to, spontaneous mechanical contraction, rhythmic mechanical contraction, synchronous mechanical contraction, and propagative mechanical contraction.

As is shown in Figure 16h of the Examples section below, the cells and tissues of the present invention can be generated displaying spontaneous mechanical contraction and rhythmic mechanical contraction. As observed visually, as described in the Examples section below, and as can be deduced from Figure 9c of the following Examples section, the cells and tissues of the present invention can be generated displaying synchronized mechanical contraction and propagative mechanical contraction.

The rhythmic mechanical contraction of the cells and tissues of the present invention exhibit cardiac specific chronotropic responses to pharmacological agents. Preferably, the cells and tissues of the present invention display chronotropic responses to catecholamines such as isoproterenol, carbamylcholine, adenylate cyclase activators such as forskolin, phosphodiesterase inhibitors such as IBMX, atropine, and diltiazem hydrochloride. As is shown in the Examples section which follows, the cells and tissues of the present invention display cardiac specific increases in mechanical contraction rhythm in response to forskolin, the phosphodiesterase inhibitor IBMX, and isoproterenol, and cardiac specific, decreases in mechanical contraction rhythm in response to muscarinic antagonists such as carbamylcholine, and atropine mediated reversal of decreases in mechanical contraction rhythm in response to muscarinic antagonists such as carbamylcholine.

The cells and tissues of the present invention further display types of cardiac specific structures including, for example, sarcomeres, Z-bands, intercalated discs, gap junctions, desmosomes, fibrillar bundles, fibrillar bundle striations, myocytic syncytia, and mononuclear cells, about 10–30  $\mu\text{m}$  in diameter, with round or rod-shaped morphology characteristic of immature cardiomyocytes, as described in Example 1 of the Examples section which follows.

The cells and tissues of the present invention further display expression of cardiac specific RNAs encoding proteins such as, for example, cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain,  $\alpha$ -actinin, cardiac troponin I, cardiac troponin T, GATA-4, Nkx2.5, MLC-2A, MLC-2V, atrial myosin light chain, ventricular myosin light chain, and connexin-43, as is demonstrated in Figure 5 of the Examples section.

The cells and tissues of the present invention still further display cardiac specific proteins including, for example, cardiac  $\alpha$ - and  $\beta$ -myosin heavy chains, atrial natriuretic peptide, cardiac troponin I, desmin and connexin-43, as is

illustrated in Figures 4b, 4f, 20c, 4e, and 8b, respectively, of the Examples section below.

The cells and tissues of the present invention additionally display types of cardiac specific electrical activity such as, for example, spontaneous electrical activity, rhythmic electrical activity, and synchronized/propagative electrical activity, as is demonstrated in Figures 9b, 6c, and 9c, respectively, of the following Examples section.

The cells and tissues of the present invention yet additionally display types of cardiac specific changes in the intracellular concentration of a physiological ion including, for example, cardiac specific changes in the intracellular concentration of  $\text{Ca}^{2+}$ , for example in the form of calcium transients, as is illustrated in Figures 6a-b of the Examples section below.

Thus, as is shown in the Examples section which follows, the cells and tissues of the present invention display cardiac specific mechanical contraction, cardiac specific structures, expression of cardiac specific RNAs, expression of cardiac specific proteins, cardiac specific changes in the intracellular concentration of a physiological ion, and/or cardiac specific electrical activity. The cells and tissues of the present invention therefore uniquely display a broad spectrum of human specific and cardiac specific structural and functional characteristics relative to prior art cultured differentiable cell-derived cells and tissues.

The propagative electrical activity of the cells and tissues of the present invention exhibit cardiac specific responses to pharmacological agents. Preferably, the cells and tissues of the present invention can display slowing of conduction in response to exposure to suitable concentrations of fast sodium channel blockers, such as 1-heptanol, tetrodotoxin (TTX), and to suitable increases in extracellular potassium ion, as is described in Example 2 of the Examples section which follows.

As is described in Example 1 of the Examples section which follows, the cells and tissues of the present invention display characteristics associated with a

cardiac phenotype for at least 60 days. This extended period of time during which the cells and tissues of the present invention display such characteristics represents a large improvement over that of cells and tissues generated via prior art methods which do not, for example, have the capacity to display highly functional mechanical contraction for extended periods of time.

The above described characteristics of the cells and tissues of the present invention imply that these cells and tissues have the capacity to functionally integrate with primary cardiac cells and tissues *in-vitro* and *in-vivo*. Preferably, such functional integration comprises formation of an integrated excitatory/excitable cardiomyocytic syncytium with primary cardiac cell and tissues. As is shown in Figures 15a and 19c-d, respectively, of the Examples section which follows, the cells and tissues of the present invention have the capacity to form an integrated excitable/excitatory cardiomyocytic syncytium with primary ventricular cardiomyocytes *in-vitro* and with myocardium *in-vivo*.

The cells and tissues of the present invention also display substantial proliferative qualities. Preferably, such proliferation is characterized by a proliferation index of at least about 10 %, more preferably at least about 20 %, yet more preferably at least about 30 %, still more preferably at least about 40 %, yet still more preferably about 50 % and most preferably at least about 60 %. As shown in Example 4 of the following Examples section, the cells and tissues of the present invention may display a proliferative index of about 60 %.

Thus, the method of the present invention can be used to generate highly differentiated, highly functional, proliferating human cells and tissues displaying a broad range of cardiac functional and structural characteristics, which cells and tissues having a potent capacity of functionally integrating with primary cardiac tissues, such as myocardium, *in-vivo*.

As such, the isolated cells and tissues generated by the method of the present invention can be optimally employed, for example, in various therapeutic, pharmacological, analytic, and modeling applications discussed herein.

Thus, according to another aspect of the present invention, there is provided a method of repairing cardiac tissue in a human subject.

The method is preferably applied to repair cardiac tissue in a human subject having a cardiac disorder so as to thereby treat the disorder. The method  
5 can also be applied to repair cardiac tissue susceptible to be associated with future onset or development of a cardiac disorder so as to thereby inhibit such onset or development.

The present invention can be advantageously used to treat disorders associated with, for example, necrotic, apoptotic, damaged, dysfunctional or  
10 morphologically abnormal myocardium. Such disorders include, but are not limited to, ischemic heart disease, cardiac infarction, rheumatic heart disease, endocarditis, autoimmune cardiac disease, valvular heart disease, congenital heart disorders, cardiac rhythm disorders, and cardiac insufficiency. Since the majority of cardiac diseases involve necrotic, apoptotic, damaged, dysfunctional  
15 or morphologically abnormal myocardium, and since the cells and tissues of the present invention display a highly differentiated, highly functional, and proliferating cardiomyocytic phenotype, the method of repairing cardiac tissue of the present invention can be used to treat the majority of instances of cardiac disorders.

20 According to a preferred embodiment, the method according to this aspect of the present invention can be advantageously used to efficiently reverse, inhibit or prevent cardiac damage caused by ischemia resulting from myocardial infarction.

According to another embodiment, the method according to this aspect of  
25 the present invention can be used to treat cardiac disorders characterized by abnormal cardiac rhythm, such as, for example, cardiac arrhythmia.

As used herein the phrase "cardiac arrhythmia" refers to any variation from the normal rhythm of the heart beat, including, but not limited to, sinus arrhythmia, premature beat, heart block, atrial fibrillation, atrial flutter, pulsus  
30 alternans and paroxysmal tachycardia.



As described in the Examples section which follows, the cells and tissues of the present invention form excitable/excitatory cardiomyocytic syncytia with primary cardiac cells and tissues *in-vitro* and with myocardium *in-vivo*, and furthermore display pace-making capacity in the context of such syncytia. Thus, the cells and tissues of the present invention can be used, for example, to provide pace-making activity to impaired myocardium and to treat an abnormal cardiac rhythm when administered to impaired cardiac tissue *in-vivo*.

The method according to this aspect of the present invention is effected by administering a therapeutically effective dose of the cells and/or tissues of the present invention to the heart of the subject, preferably by injection into the heart of the subject. As used herein, a therapeutically effective dose is an amount sufficient to effect a beneficial or desired clinical result, which dose could be administered in one or more administrations. Preferably, a single administration is employed. The injection can be administered into various regions of the heart, depending on the type of cardiac tissue repair required. Administration is preferably intramyocardial. Intramyocardial administration is particularly advantageous for repairing cardiac tissue in a subject having a cardiac disorder characterized by cardiac arrhythmia or myocardial ischemia.

Such administration directly into cardiac tissue ensures that the administered cells/tissues will not be lost due to the contracting movements of the heart.

The cells and tissues of the present invention can be administered via transendocardial or transepicardial injection, depending on the type of cardiac tissue repair being effected, and the physiological context in which the cardiac repair is effected. This allows the administered cells or tissues to penetrate the protective layers surrounding membrane of the myocardium.

Preferably, a catheter-based approach is used to deliver a transendocardial injection. The use of a catheter precludes more invasive methods of delivery wherein the opening of the chest cavity would be necessitated. As one skilled in the art is aware, optimum time of recovery would be allowed by the more

minimally invasive procedure, which as outlined here, includes a catheter approach.

In Example 3 of the Examples section which follows, a dose of 20–40 contracting embryoid bodies (each embryoid body containing approximately 20,000 cells) was injected into cardiac tissue of impaired hearts of pigs weighing twenty to thirty kilograms. Such a dose of injected cells restored cardiac functionality, by forming a functionally integrated excitable/excitatory cardiomyocytic syncytium and providing pacemaking activity thereto. Thus, the results presented herein clearly provide and approach for repairing cardiac tissue in a subject having a cardiac disorder associated with cardiac arrhythmia or ischemic myocardium.

In the case of repairing cardiac tissue in a subject having a cardiac disorder characterized by cardiac arrhythmia, electrophysiological mapping of the heart and/or inactivation of cardiac tissue by radiofrequency treatment may be advantageously performed in combination with administration of the cells and tissues of the present invention if needed. As described in detail in Example 3 of the Examples section, the cells and tissues of the present invention can be used to confer pace-making activity to myocardium inactivated by radiofrequency treatment.

To repair cardiac tissue damaged by ischemia, for example due to a cardiac infarct, the cells and tissues of the present invention are preferably administered to the border area of the infarct. As one skilled in the art would be aware, the infarcted area is grossly visible, allowing such specific localization of application of therapeutic cells to be possible. The precise determination and timing of an effective dose in this particular case may depend, for example, on the size of an infarct, and the time elapsed following onset of myocardial ischemia.

Preferably, administration of the cells/tissues of the present invention for repair of damaged myocardium is effected following sufficient reduction of

inflammation of affected cardiac tissues and prior to formation of excessive scar tissue.

As mentioned hereinabove, the present invention can be used to generate cardiomyocytic cells and tissues displaying a desired proliferative capacity, thus  
5 cells and tissues are preferably selected displaying a suitable proliferative capacity for administration, depending on the type of cardiac tissue repair being effected. Administration of highly proliferative cells may be particularly advantageous for reversing myocardial damage resulting from ischemia since, as previously described, it is the essential inability of normal adult cardiomyocytes  
10 to proliferate which causes the irreversibility of ischemia induced myocardial damage.

Since porcine models are widely considered to be excellent models for human therapeutic protocols and since such models have been widely employed and characterized, it is well within the grasp of the ordinarily skilled artisan to  
15 determine a therapeutically effective dose for a human based on the guidance provided herein, and on that provided by the extensive literature of the art.

Preferably, determination of an effective dose can further be based on factors individual to each subject, including, for example, weight, age, physiological status, medical history, and parameters related to the cardiac  
20 disorder, such as, for example, infarct size and elapsed time following onset of ischemia. One skilled in the art, specifically a cardiologist, would be able to determine the number of the cells and tissues of the present invention that would constitute an effective dose, and the optimal mode of administration thereof without undue experimentation.

25 It will be recognized by the skilled practitioner that when administering non-syngeneic cells or tissues to a subject, there is routinely immune rejection of such cells or tissues by the subject. Thus, the method of the present invention preferably further comprises treating the subject with an immunosuppressive regimen, preferably prior to such administration, so as to inhibit such rejection.  
30 Immunosuppressive protocols for inhibiting allogeneic graft rejection, for

example via administration of cyclosporin A, immunosuppressive antibodies, and the like are widespread and standard practice in the clinic.

The treatment method of this aspect of the present invention can be effected by administering the cells and tissues of the present invention as isolated  
5 cells or tissues or as an engineered cardiomyocytic tissue having a therapeutically useful two or three-dimensional form.

Engineered cardiomyocytic tissues can be generated via standard tissue engineering techniques, for example by seeding a tissue engineering scaffold having the designed form with the cells and tissues of the present invention and  
10 culturing the seeded scaffold under conditions enabling colonization of the scaffold by the seeded cells and tissues, thereby enabling the generation of the formed cardiac tissue. The formed tissue is then administered to the cardiac tissue of the recipient, for example using standard surgical implantation techniques. Suitable scaffolds may be generated, for example, using  
15 biocompatible, biodegradable polymer fibers or foams, comprising extracellular matrix components, such as, laminins, collagen, fibronectin, etc. Detailed guidelines for generating or obtaining suitable scaffolds, culturing such scaffolds and therapeutically implanting such scaffolds are available in the literature of the art (for example, refer to Kim SS. and Vacanti JP., 1999. Semin Pediatr Surg.  
20 8:119; U.S. Pat. No. 6387369 to Osiris Therapeutics, Inc.; U.S. Pat. App. No. US20020094573A1 to Bell E.).

Thus, the method of repairing cardiac tissues of the present invention, by virtue of its uniqueness in utilizing *in-vitro* culture of human differentiable cells to generate essentially unlimited numbers of highly differentiated, highly  
25 functional and proliferating cardiomyocytic cells and tissues is far superior to all prior art methods.

According to yet another aspect of the present invention, there is provided a method of characterizing biological states and biological processes of cardiac cells and cardiac tissues.

As used herein, "characterizing" a state or process refers to generating data or obtaining information defining or describing such a state or process.

Since the cells and tissues of the present invention display an exceptionally broad spectrum of human and cardiac specific characteristics, and since the present invention can be used to generate essentially unlimited quantities of such cells and tissues, such cells and tissues can be used to accurately model *in-vitro* and *in-vivo* a very broad range of cardiac specific biological states and processes. Furthermore, since the method of the present invention can be used to generate cells and tissues displaying high cardiac functionality for at least up to 60 days in culture, the present invention can advantageously be employed to characterize cardiac specific biological states and processes over extended periods of time. Thus, the method of the present invention can uniquely be used to characterize substantially long-term processes such as, for example, human cardiac physiology and human cardiac development. For example, as is shown in Figure 4 of the Examples section below, the method can be used to characterize the long-term development of cardiac cells and tissues *in-vitro*.

As described in detail hereinabove and in the Examples section hereinbelow, the method can be used to characterize biological states and processes corresponding to all of the characteristics associated with a cardiac phenotype displayed by the cells and tissues of the present invention described hereinabove, such as cardiac specific mechanical contraction, cardiac specific structures, expression of cardiac specific RNAs, expression of cardiac specific proteins, cardiac specific changes in the intracellular concentration of a physiological ion, cardiomyogenesis and most preferably cardiac specific electrical activity.

As used herein, the word "cardiomyogenesis" refers to any process of growth and/or differentiation of cardiac cells or tissues.

By virtue of enabling characterization of gene transcription in the cells and tissues of the present invention, the method according to this aspect of the



present invention can be advantageously used to obtain comprehensive profiles of cardiac specific gene expression, such as for example gene expression profiles related to cardiomyocytic growth and differentiation, or gene expression profiles related to a characteristic associated with a cardiac phenotype, as described  
5 hereinabove.

Thus, the method according to this aspect of the present invention can be advantageously employed to identify novel cardiac specific genes, such as novel cardiac specific genes related to growth and differentiation of cardiac cells and tissues, or novel cardiac specific genes associated with a characteristic associated  
10 with a cardiac phenotype, as described hereinabove.

Due to the proliferative capacity of the cells and tissues of the present invention, the method according to this aspect of the present invention may be advantageously employed to characterize biological states and processes related to growth and differentiation of cardiac cells.

15 The method of characterizing biological states and processes is preferably effected by generating the cells and tissues of the present invention, essentially as described hereinabove and in the Examples section below, and obtaining data characterizing selected biological states or biological processes in such cells and tissues. Obtaining such data is effected essentially as described hereinabove for  
20 screening characteristics associated with a cardiac phenotype in such cells and tissues.

As described hereinabove and in the Examples section below, the cardiac cells and tissues of the present invention possess the capacity to functionally integrate with primary cardiac cells and tissues *in-vitro* or with primary cardiac  
25 tissue *in-vivo*. Thus, the method according to this aspect of the present invention can further comprise co-culturing the cells or tissues of the present invention with primary cardiac cells or primary cardiac tissue prior to obtaining data characterizing a biological states or process of such cells and tissues, as described in the Examples section which follows.

30 As is illustrated in Figure 15b and described in the Examples section

below, biological states and processes characterized by cardiac specific chronotropic responses can be induced in integrated myocytic syncytia comprising the cells and tissues of the present invention and primary cardiomyocytes.

5 Alternately, the method may include transplanting the cells or tissues of the present invention into cardiac tissue of a recipient prior to obtaining data characterizing a biological state or process of such cells and tissues. Preferably the recipient is a swine. Such co-culturing or transplanting can be used to characterize biological states and processes of cardiac cells and tissues to which  
10 the cells and tissues of the present invention have been applied. This type of characterization provides important information, for example, for optimizing and testing strategies for therapeutic transplantation of cardiac cells and tissues. As is shown in Example 3 of the Examples section which follows, transplantation can be used to characterize development of the cardiac rhythm of the cells and tissues  
15 of the present invention in an *in-vivo* transplantation context.

The method according to this aspect of the present invention may further comprise a step of inducing such biological states and processes in the cells and tissues of the present invention prior to obtaining data characterizing a biological state or process. As described in the following Examples section and  
20 hereinabove, the cells and tissues of the present invention display various cardiac specific biological states or processes in response to pharmacological and electrical treatments. Preferably, the method is used to induce abnormal states and processes in the cells and tissues of the present invention, thereby enabling characterization of cardiac disorders associated with such abnormal states. As  
25 described in detail hereinabove and the following Examples section, various treatments can be used to induce cardiac specific chronotropic responses or cardiac specific changes in conduction of propagative electrical activity. For example, as is demonstrated in Example 2 of the following Examples section, increasing extracellular potassium concentration or treatment with tetrodotoxin

or 1-heptanol can be used to induce slowing of propagative electrical activity conduction in the cells and tissues of the present invention.

Alternately, the cells and tissues of the present invention can be screened for cells and tissues displaying selected biological states and/or processes such as abnormal biological states and processes. As is illustrated in Figure 10b of the Examples section below, slow conduction of propagative electrical activity can be observed in embryoid bodies screened for the presence of foci of the cells and tissues of the present invention comprising two regions connected by a narrow strand of such cells and tissues, which narrow strand exhibiting the slowing of conduction.

Thus, the method according to this aspect of the present invention can be advantageously used to model various cardiac biological states and processes, including abnormal cardiac biological states and processes. Such modeling can be used, for example, for optimizing and testing strategies for therapy of cardiac disorders. As previously described hereinabove and in the Examples section below, atropine treatment can be shown to lead to the expected cardiac specific reversal of carbamylcholine induced negative chronotropic responses in the cells and tissues of the present invention.

Inducing of biological states and processes is preferably effected by treating the cells or tissues of the present invention with a treatment such as a treatment with a drug, a treatment with a physiological ion, and an electrical treatment. Alternately, inducing of biological states and processes may be effected by subjecting the cells and tissues to biomechanical stress treatment or to treatment with a growth or differentiation factor. Biomechanical stress treatment can be used, for example, to model various aspects of high blood pressure.

Preferably, the drug is selected from the group consisting of 1-heptanol, isoproterenol, carbamylcholine, forskolin, IBMX, atropine, tetrodotoxin, and diltiazem hydrochloride. As described hereinabove and in the following Examples section, these drugs can be used to induce selected biological states

and processes, such as positive and negative chronotropic responses, and slowing of propagative electrical activity conduction in the cells and tissues of the present invention.

Preferably, the physiological ion is selected from the group consisting of a potassium ion, a sodium ion, and a calcium ion. Treatment with a physiological ion can be used, for example, to induce slowing of electrical activity conduction in the cells and tissues of the present invention. As is described and shown in the Examples section which follows, elevation of extracellular potassium can be used to induce slow conduction of propagative electrical activity, a clinically relevant cardiac abnormality, in the cells and tissues of the present invention.

Thus, according to yet an additional aspect of the present invention, there is provided a method of qualifying the effect of a treatment on a biological state or a biological process of cardiac cells or cardiac tissue. Qualifying the effect of a treatment on a biological state or a biological process of the cells and tissues of the present invention, for example an abnormal biological state or process thereof, can be used to identify and optimize treatments capable of restoring the normal biological state or process, and hence can be used to identify and optimize treatments suitable for treating cardiac disorders. Furthermore, qualifying the effect of a treatment on a biological state or a biological process of cardiac cells or tissues can be used to assess the toxicity of such a treatment on such a biological state or process. Since the method can be used to characterize the effect of a treatment on cardiomyogenesis, according to one embodiment the method can be used to assess the embryotoxicity of a treatment, in particular a treatment with a compound. Thus, failure to generate a characteristic associated with a cardiac phenotype, preferably cardiac specific mechanical contraction, in the cells and tissues of the present invention in response to treatment with a compound can be used to qualify the embryotoxicity, such as the cardiac specific or systemic embryotoxicity, of such a compound.

The method of qualifying the effect of a treatment on a biological state or a biological process of cardiac cells or tissue is effected by generating the cells or

tissues of the present invention, as described hereinabove and in the Examples section below, subjecting the cells or tissues of the present invention to the treatment, and monitoring the biological state or process in such cells and tissues.

When qualifying the effect of a treatment in cells and tissues of the present invention co-cultured with primary cardiac cells or primary cardiac tissue, the treatment can be effected prior to or following such co-culturing or transplanting, allowing the determination of the effects of the treatment in these separate contexts.

Thus, this aspect of the present invention can be preferably utilized to determine the therapeutic and toxic effects of various treatments, such as drug treatments, and electrical treatments, on abnormal biological states and processes of cardiac cells and tissues, such as pathogenic biological states or processes of cardiac cells or tissues.

Hence the method of the present invention can be used to screen and/or test cardiac drugs.

This aspect of the present invention can be utilized to obtain gene expression profiles and changes thereof in cardiomyocytic cells and tissues subjected to a treatment. Thus, the method according to this aspect of the present invention can be used to determine, for example, gene expression pattern changes in response to a treatment.

Preferably, the treatment to which the cells or tissues of the present invention are subjected is an exposure to a compound or an electrical treatment. Preferably the compound is a drug, or a physiological ion. Alternately the compound can be a growth factor or differentiation factor, such as, for example, vascular endothelial growth factor (VEGF).

Exposure to a compound is preferably effected as previously described in detail hereinabove and in the Examples section which follows, for example as described for compounds inducing chronotropic responses or changes in propagative electrical activity conduction.

Exposure to an electrical treatment is preferably effected by applying an



electrical source to the cells and tissues of the present invention, for example via an electrode of a multielectrode array, as shown in Example 3 of the Examples section, or via any of the numerous suitable methods described in the literature of the art.

5        Subjecting the cells and tissues to a biomechanical stress treatment may be effected via any of numerous techniques known in the art. For example, biomechanical stress may be applied to the cells and tissues of the present invention using glass micropipettes controlled, for example, by a micromanipulating device.

10        Preferably, monitoring biological states and processes in the cells and tissues of the present invention following treatment thereof is effected as extensively detailed hereinabove and in the Examples section which follows.

Additional objects, advantages, and novel features of the present invention  
15 will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.

20

### EXAMPLES

Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a non limiting fashion.

Generally, the nomenclature used herein and the laboratory procedures  
25 utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "Molecular Cloning: A laboratory Manual" Sambrook *et al.*, (1989); "Current Protocols in Molecular Biology" Volumes I–III Ausubel, R. M., ed. (1994); Ausubel *et al.*, "Current Protocols in Molecular  
30 Biology", John Wiley and Sons, Baltimore, Maryland (1989); Perbal, "A

Practical Guide to Molecular Cloning”, John Wiley & Sons, New York (1988);  
Watson *et al.*, “Recombinant DNA”, Scientific American Books, New York;  
Birren *et al.* (eds) “Genome Analysis: A Laboratory Manual Series”, Vols. 1–4,  
Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set  
5 forth in U.S. Pat. Nos. 4, 666, 828; 4, 683, 202; 4, 801, 531; 5, 192, 659 and 5,  
272, 057; “Cell Biology: A Laboratory Handbook”, Volumes I–III Cellis, J. E.,  
ed. (1994); “Current Protocols in Immunology” Volumes I–III Coligan J. E., ed.  
(1994); Stites *et al.* (eds), “Basic and Clinical Immunology” (8<sup>th</sup> Edition),  
Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), “Selected  
10 Methods in Cellular Immunology”, W. H. Freeman and Co., New York (1980);  
available immunoassays are extensively described in the patent and scientific  
literature, see, for example, U.S. Pat. Nos. 3, 791, 932; 3, 839, 153; 3, 850, 752;  
3, 850, 578; 3, 853, 987; 3, 867, 517; 3, 879, 262; 3, 901, 654; 3, 935, 074; 3,  
984, 533; 3, 996, 345; 4, 034, 074; 4, 098, 876; 4, 879, 219; 5, 011, 771 and 5,  
15 281, 521; “Oligonucleotide Synthesis” Gait, M. J., ed. (1984); “Nucleic Acid  
Hybridization” Hames, B. D., and Higgins S. J., eds. (1985); “Transcription and  
Translation” Hames, B. D., and Higgins S. J., eds. (1984); “Animal Cell Culture”  
Freshney, R. I., ed. (1986); “Immobilized Cells and Enzymes” IRL Press, (1986);  
“A Practical Guide to Molecular Cloning” Perbal, B., (1984) and “Methods in  
20 Enzymology” Vol. 1–317, Academic Press; “PCR Protocols: A Guide To  
Methods And Applications”, Academic Press, San Diego, CA (1990); Marshak *et al.*,  
“Strategies for Protein Purification and Characterization – A Laboratory  
Course Manual” CSHL Press (1996); all of which are incorporated by reference  
as if fully set forth herein. Other general references are provided throughout this  
25 document. The procedures therein are believed to be well known in the art and  
are provided for the convenience of the reader. All the information contained  
therein is incorporated herein by reference.

**EXAMPLE 1*****Generation of highly differentiated, highly functional cardiomyocytic cells via in-vitro culture of human embryonic stem cells***

Despite decades of intensive research, heart failure remains the primary  
5 cause of death and, to date, there do not exist satisfactory methods of generating  
cardiomyocytic cells which could be used therapeutically or as a satisfactory *in-*  
*vitro* model of cardiac development and function. Thus, in order to fulfill this  
critical need, the present inventors have generated for the first time *in-vitro*  
functional embryonic stem cell-derived cardiomyocytic cells, as follows.

**10 *Materials and Methods:******Generation of human embryonic stem cell-derived cardiomyocytic cells:***

Ten different human embryonic stem cell lines including line H9 or its single cell  
clonal derivative H9.2 (Amit, M. *et al.*, 2000. Dev. Biol. 227:271) were  
individually grown on a mitotically inactivated (mitomycin C) mouse embryonic  
15 fibroblast feeder cell layer in culture medium, as previously described (Thomson,  
J.A. *et al.*, 1998. Science 282:1145). The culture medium consisted of 80 %  
knockout DMEM (no-pyruvate, high-glucose formulation; Life Technologies,  
Inc., Rockville, Maryland, USA.) supplemented with 20 % FBS (HyClone,  
Logan, Utah, USA.), 1 mM L-glutamine, 0.1 mM mercaptoethanol, and 1 %  
20 nonessential amino acid stock (all from GIBCO-BRL).

To induce differentiation, embryonic stem cells were dispersed into small  
clumps (3–20 cells) using collagenase IV (Life Technologies, Inc., 1 mg/ml for  
20 minutes). Dispersion of embryonic stem cells using trypsin, as is routinely  
used to generate cardiomyocytic cells from murine embryonic stem cells, was  
25 found to be highly damaging, leading, for example, to a high incidence of  
abnormal karyotypes.

The cells were then transferred to plastic Petri dishes (Miniplast, Ein  
Shemer, Israel), at a cell density of about  $5 \times 10^6$  cells in a 58 mm dish, where  
they were cultured under nonadherent conditions for 7–10 days. During this  
30 stage the cells aggregated to form embryoid bodies, which were then plated on

0.1 % gelatin-coated culture dishes and observed microscopically for the appearance of spontaneous contractions. The different stages in generation of embryonic stem cell-derived cardiomyocytic cells are summarized in Figure 1a.

In order to assess the efficacy of the cardiomyocyte differentiation system, a total of 1,884 embryoid bodies were plated on gelatin-coated dishes and monitored microscopically daily for the presence of contractions for up to 30 days postplating. The percentage of embryoid bodies displaying contracting areas, as well as the distribution of the timing of onset of spontaneous beating were evaluated. In a preliminary study, it was noted that varying embryonic stem cell density input in the suspension phase, while modifying the number of embryoid bodies produced, did not affect the percentage of beating embryoid bodies. Similarly, screening of two different lots of serum also did not modify the cardiomyocytic cell yield significantly. In addition, the effect of DMSO, a known stimulant of differentiation into cardiomyocytic lineage was assessed by adding dimethyl sulfoxide (Sigma Chemical Co., St. Louis, Missouri, USA.) at a concentration of 0.75 % (vol/vol) to the culture medium during the 10 days of growth in suspension. The percentage of contracting embryoid bodies as well as the timing of onset of spontaneous contractions were examined microscopically.

**Immunostaining:** Contracting areas were mechanically dissected using a pulled-glass micropipette and enzymatically dispersed using trypsin-EDTA (0.5 % trypsin, 0.53 mM EDTA; Life Technologies, Inc.) for 15 minutes at 37 °C. The dispersed cells were plated on laminin-coated glass coverslips, incubated for 48 h, fixed in 4 % paraformaldehyde with sucrose, and permeated using 0.5 % Triton X-100 (Sigma). The fixed and permeated cells were blocked with 10 % BSA and incubated with primary antibody overnight at 4°C. Labelling with primary antibody was performed using mAbs specific for myosin cardiac heavy chain  $\alpha/\beta$  at a dilution of 1:50, mAbs specific for cardiac muscle troponin I at a dilution of 1:5000, mAbs specific for desmin at a dilution of 1:100, and polyclonal antibody specific for atrial natriuretic peptide at a dilution of 1:250 (all from CHEMICON International, Inc., Temecula, California, USA.). Staining

of sarcomeric  $\alpha$ -actinin and nebulin was performed using anti sarcomeric  $\alpha$ -actinin mAbs at a dilution of 1:800 and anti nebulin mAbs at a dilution of 1:200 (both from Sigma), respectively. Following three washes with PBS, primary antibody stained cells were incubated with: FITC-conjugated donkey anti mouse  
5 IgG absorbed against human tissue for cardiac myosin heavy chain, desmin, and troponin I staining; or rhodamine-conjugated anti rabbit IgG for  $\alpha$ -actinin, atrial natriuretic peptide, and nebulin staining (both from CHEMICON International) at a dilution of 1:100 for 1 h at room temperature. Immunostained preparations were examined by fluorescence microscopy. Dispersed cells isolated from  
10 noncontracting embryoid bodies served as controls.

**RT-PCR:** Total RNA from undifferentiated embryonic stem cells and contracting embryoid bodies was extracted using TRI reagent kit (Sigma), according to the manufacturer's instructions. Complementary DNA (cDNA) was synthesized from 1  $\mu$ g total RNA using SuperScript II reverse transcriptase (Life  
15 Technologies, Inc.) and used as template for PCR amplifications with primers selective for human cardiac genes. The PCR primers and the reaction conditions used are listed in Table 1. The PCR products were size fractionated by 2 % agarose gel electrophoresis.

**Transmission electron microscopy:** For transmission electron  
20 microscopy, the spontaneously contracting areas were mechanically dissected, fixed in 3 % glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4, at 4 °C for 24 h, postfixed in 1 % OsO<sub>4</sub> in the same buffer for 1 h, dehydrated in graded ethanols, and embedded in Epon 812. Thin sections (250–300 nm) were used for ultrastructural evaluation using a JEOL 100 SX transmission electron microscope  
25 (Peabody, Massachusetts, USA.) operating at 80 kV.

**Multielectrode array (MEA) extracellular electrophysiology mapping and pharmacological studies:** Intact contracting areas within the embryoid bodies were mechanically dissected using a pulled-glass micropipette and plated on gelatin-coated multielectrode arrays (Multi Channel Systems MCS GmbH,  
30 Reutlingen, Germany; Igelmund, P. *et al.*, 1999. Pflügers Arch. 437:669). The



microelectrode array consists of 60 titanium nitride electrodes with gold contacts 30  $\mu\text{m}$  in diameter with an interelectrode distance of 100–200  $\mu\text{m}$ . The contracting areas were plated on top of the microelectrode arrays and cells were grown to confluence over the electrodes. In some embryoid bodies with relatively small contracting areas, the contracting area did not cover all electrodes, and hence recordings were performed from fewer than 60 electrodes. Extracellular signals were recorded simultaneously from all 60 electrodes at 25 kHz and band-pass filtered from 1 to 3000 Hz. Recordings were performed in culture medium at 37 °C. A pH of 7.4 was maintained using perfusion with an atmosphere containing 5 % CO<sub>2</sub> and 95 % air.

**Table 1. PCR primers employed**

Gene product*	Primer pairs	Reaction conditions			Product size (bp)
		# cycles	T <sub>A</sub> ** (°C)	MgCl <sub>2</sub> (mM)	
hANP	GAACCAGAGGGGAGAGACAGAG (SEQ ID NO: 1) CCCTCAGCTTGCTTTTAGGAG (SEQ ID NO: 2)	35	61	1	406
MHC-2A	ACAGAGTTTATTGAGGTGCCCC (SEQ ID NO: 3) AAGGTGAAGTGTCCTCAGAGG (SEQ ID NO: 4)	35	61	1	381
MHC-2V	TATTGGAACATGGCCTCTGGAT (SEQ ID NO: 5) GGTGCTGAAGGCTGATTACGTT (SEQ ID NO: 6)	35	61	1	382
GATA-4	AGACATCGCACTGACTGAGAAC (SEQ ID NO: 7) GACGGGTCCTATCTGTGCAAC (SEQ ID NO: 8)	30	60	1	475
$\alpha$ -MHC	GTCATTGCTGAAACCGAGAATG (SEQ ID NO: 9) GCAAAGTACTGGATGACACGCT (SEQ ID NO: 10)	40	61	2	413
Oct-4	GAGAACAAATGAGAACCTTCAGGAGA (SEQ ID NO: 11) TTCTGGCGCCGGTTACAGAACCA <sup>§</sup> (SEQ ID NO: 12)	35	55	1.5	219
Nk $\alpha$ 2.5	CTTCAAGCCAGAGGCCTACG (SEQ ID NO: 13) CCGCCTCTGTCTTCTTCAGC <sup>†</sup> (SEQ ID NO: 14)	35	55	1.5	233
cTnT	GGCAGCGGAAGAGGATGCTGAA (SEQ ID NO: 15) GAGGCACCAAGTTGGGCATGAACGA <sup>‡</sup> (SEQ ID NO: 16)	35	60	1.5	150
cTnI	CCCTGCACCAGCCCAATCAGA (SEQ ID NO: 17) CGAAGCCCAGCCCGGTCAACT <sup>‡</sup> (SEQ ID NO: 18)	35	60	1.5	250
GAPDH	AGCCACATCGCTCAGACACC (SEQ ID NO: 19) GTACTCAGCGGCCAGCATCG <sup>‡</sup> (SEQ ID NO: 20)	25	61	1.5	302

\* hANP – human atrial natriuretic peptide, MHC – myosin heavy chain, Oct-4 – octamer-binding protein-4; <sup>§</sup> (Abdel-Rahman, B. *et al.*, 1995. Hum. Reprod. 10:2787-2792); <sup>†</sup> (Shiojima *et al.*, 1996. Circ. Res. 79:920-929); (Ricchiuti V. and Apple S., 1999. Clin. Chem. 45:2129-2135);

<sup>‡</sup> (Itskovitz-Eldor *et al.*, 2000. Mol. Med. 6:88-95); \*\* annealing temperature

Chronotropic responses were assessed by extracellular recordings for 10 minutes prior to and following replacement of the culture medium with culture media containing 1  $\mu$ M isoproterenol, 1  $\mu$ M carbamylcholine, 10  $\mu$ M 3-isobutyl-1-methylxanthine (IBMX), or 1  $\mu$ M forskolin (all from Sigma).

5        **Measurement of intracellular calcium ( $[Ca^{2+}]_i$ ) transients:** The embryoid bodies were loaded with fura-2-AM (Molecular Probes, Eugene, Oregon, USA.) for 25 minutes at room temperature (24–25°C) at a final concentration of 5  $\mu$ M, in a 1:1 mixture of Tyrode's solution. The dye loaded embryoid bodies were then transferred to a nonfluorescent chamber mounted on the stage of an inverted  
10        microscope (Diaphot 300, Nikon, Tokyo, Japan). The chamber was perfused with Tyrode's solution at a rate of 1 ml/minute and the temperature in the chamber was maintained at 37 °C. Fura-2 fluorescence was measured using a dual-wavelength system (Deltascan, Photon Technology International [PTI], New Jersey, USA.) as previously described (Felzen, B. *et al.*, 1998. Circ. Res.  
15        82:438). Briefly, two different wavelengths (340 and 380 nm) were used for excitation, and the emitted fluorescence (510 nm) was collected and detected by a photomultiplier tube (710 PMT, photomultiplier detection system; PTI). Raw data were stored for off-line analysis using the Felix software (PTI) as 340 nm and 380 nm counts and as the ratio  $R = F_{340}/F_{380}$ . The Savitzky-Golay smoothing  
20        algorithm was used to reduce noise level.

**Statistical analysis:** Data are expressed as mean  $\pm$  standard deviation. In order to assess possible chronotropic effects, the average spontaneous beating rate was compared prior to and following drug application using two-tailed paired Student's t test. P values less than 0.05 were considered significant.

25        **Experimental Results:**

**Human embryonic stem cell-derived cardiomyocytic cells form spontaneously contracting areas:**

Typical examples of embryonic stem cell colonies grown on top of the mouse embryonic fibroblast feeder layer, the formation of embryoid bodies  
30        during the suspension phase, and an embryoid body containing a contracting area

following plating are shown in Figures 1b-d, respectively. Out of the ten different embryonic stem cell lines subjected to the culturing protocol described above in the Materials and Methods section, only embryoid bodies derived from line H9.2 displayed a significant incidence of cardiomyocytic differentiation.

5 Thus, all results presented herein were generated using cell line H9.2.

Embryoid bodies were found to develop rhythmically contracting areas between 4 and 22 days postplating, as shown in Figure 2 which illustrates the cumulative percentage of embryoid bodies containing contracting areas as a function of days postplating. Such contracting areas appeared in 153 (8.1 %) of the 1,884 embryoid bodies studied. In contrast, the incidence of spontaneous contraction observed in embryoid bodies derived the H9.2 parental line H9 was about 0.1 %. The onset of contractions peaked between 6 and 11 days postplating, when contracting areas appeared in 4.9 % of the embryoid bodies. The contracting areas usually appeared in the outgrowth of the embryoid bodies, displayed diameters ranging between 0.2 and 2 mm, and continued to beat vigorously for up to 60 days, the longest period studied. The presence of DMSO at a concentration of 0.75 % increased the percentage of embryoid bodies demonstrating contracting areas to 10.1 %.

*Human embryonic stem cell-derived cardiomyocytic cells form organized sarcomeric structures, Z-bands, intercalated discs, gap junctions and desmosomes:* Light microscopy revealed that the contracting areas were composed mainly of relatively small mononuclear cells, 10–30  $\mu\text{m}$  in diameter, with round or rod-shaped morphology. Transmission electron microscopy of these cells revealed mononuclear cells displaying parallel arrays of myofibrillar bundles oriented in an irregular manner in some cells (Figure 3a), while a more mature sarcomeric organization was apparent in others (Figures 3, b and c). The degree of myofibrillar organization varied within different areas of the same cell, among different cells in the same embryoid body, and among different embryoid bodies. Nevertheless, in general, a shift from an immature phenotype manifested by disorganized myofibrillar stacks in early stage embryoid bodies (Figure 3a) to

a more organized sarcomeric structure in later stage embryoid bodies (Figures 3b-c) was noted. In some foci, the formation of early and more developed Z bands could be observed (Figures 3b-c). The intercalated disc, another cellular structure that characteristically appears during *in-vivo* cardiomyocyte differentiation, was observed in many of the differentiating embryoid bodies. Intercalated discs composed of gap junctions and desmosomes were observed to connect adjacent cells (Figures 3d-e).

*Display of fibrillar bundle striation and expression of cardiac muscle specific, but not skeletal muscle specific proteins, by cultured human embryonic stem cell-derived cardiomyocytic cells:* Using immunocytochemistry, the presence of cardiac-specific proteins and their spatial organization were studied in dispersed cells forming contracting embryoid bodies. Figure 4a shows positive immunostaining of dispersed myocytes with anti cardiac  $\alpha/\beta$ -myosin heavy chain mAbs. Varying degrees of myofibrillar organization were noted among the cells. The staining patterns ranged from cytoplasmic clumps in some cells to nonparallel bundles of elongated fibrillar structures in others. Some of these bundles displayed an early striated pattern (Figure 4b). The contracting myocytes also stained positively with anti  $\alpha$ -actinin mAbs (Figure 4c), anti cTnI mAbs (Figure 4d), and anti desmin mAbs (Figure 4e), with different cells demonstrating varying degrees of sarcomeric organization. In addition, the speckled perinuclear staining by anti atrial natriuretic peptide (Figure 4f) suggested the presence of cytoplasmic atrial natriuretic peptide granules. In contrast to the positive staining with cardiac-specific proteins, cells from the contracting areas did not demonstrate nebulin immunoreactivity, confirming the cardiomyocytic, rather than skeletal, nature of the cells (Begum, S. *et al.*, 1998. Cell Tissue Res. 293:305).

In order to determine the percentage of cardiomyocytic cells in the contracting areas, the regions exhibiting spontaneous contracting activity were microdissected, enzymatically dispersed, and plated at low density to allow

identification of individual cells by immunocytochemistry. Using anti cTnI mAbs, the percentage of positively stained cells was found to be 29.4 %.

*Cultured human embryonic stem cell-derived cardiomyocytic cells exhibit expression of cardiac specific genes:* The expression of several cardiac-specific genes was assessed in the cultured human embryonic stem cell-derived cardiomyocytic cells and in undifferentiated human embryonic stem cells using RT-PCR. As shown in Figure 5, myocytes from contracting embryoid bodies expressed the cardiac transcription factors GATA-4 and Nkx2.5 as well as the cardiac-specific genes cTnI, cardiac troponin T (cTnT), atrial myosin light chain (MLC-2A), ventricular myosin light chain (MLC-2V), and  $\alpha$ -myosin heavy chain. GATA-4 and MLC-2A expression was also noted in the undifferentiated embryonic stem cells, but was markedly increased in the contracting embryoid bodies. Octamer-binding protein 4, a marker of undifferentiated cells, was expressed in the embryonic stem cells. This expression significantly declined in the contracting embryoid bodies. The housekeeping gene GAPDH served as an internal control.

*Display of synchronous contractions and cardiac specific intracellular calcium transients by cultured human embryonic stem cell-derived cardiomyocytic cells:* Intracellular calcium transients ( $[Ca^{2+}]_i$ ) were measured from spontaneously contracting embryoid bodies using fura-2 ( $n = 7$ ). Figure 6a displays a typical recording with an initial rise in systolic  $[Ca^{2+}]_i$  and a slower decay. The time to peak systolic  $[Ca^{2+}]_i$  averaged  $130 \pm 27$  milliseconds, the time to half-peak relaxation was  $143 \pm 94$  milliseconds, and total transient length was  $465 \pm 180$  milliseconds. In all cases, the  $[Ca^{2+}]_i$  signals were synchronous with the contraction rate observed microscopically. Figure 6b depicts a continuous recording.

*Human embryonic stem cell-derived cardiomyocytic cells exhibit cardiomyocyte specific extracellular electrophysiology and chronotropic responses to pharmacological agents:* Extracellular recordings from the contracting areas displayed electrograms consisting of a sharp component with a



peak-to-peak amplitude of  $630 \pm 33 \mu\text{V}$  lasting  $30 \pm 25$  milliseconds, followed by a slow component of  $347 \pm 120$  milliseconds, representing the depolarization and repolarization processes, respectively (Figure 6c). The average spontaneous beating rate was  $94 \pm 33$  beats/minute ( $n = 8$ ) and was stable (mean frequency standard deviation of 1.55 beats/minute) during a recording period of 20 minutes in all embryoid bodies studied.

Positive and negative chronotropic responses were observed following administration of the  $\beta$ -agonist isoproterenol and the muscarinic agonist carbamylcholine, respectively. Isoproterenol at  $10^{-6}$  M significantly increased spontaneous contraction rate to  $146 \pm 43$  % of its baseline value ( $n = 8$ ;  $P < 0.01$ ). Similarly, the direct adenylate cyclase activator forskolin and the phosphodiesterase inhibitor IBMX increased spontaneous contraction rate to  $182 \pm 48$  % ( $n = 6$ ;  $P < 0.01$ ) and  $152 \pm 77$  % ( $n = 6$ ;  $P < 0.05$ ) of its initial value. In contrast, the muscarinic agonist carbamylcholine at  $10^{-6}$  M decreased the rate to  $78 \pm 20$  % of its initial value ( $n = 6$ ;  $P < 0.05$ ). The latter effect was reversed by application of the muscarinic antagonist atropine. All the above responses were prompt, occurring within 90 seconds of drug application.

**Analysis:** The present invention provides a novel and reproducible system in which human embryonic stem cells differentiate into cardiomyocytic cells and tissue. These results demonstrate that the spontaneously contracting tissue within the developing embryoid bodies contain cardiomyocytic cells portraying structural and functional properties consistent with early stage cardiac tissue.

Several lines of evidence confirm the cardiomyocytic nature of these embryonic stem cell-derived cells. Ultrastructural analysis showed that these cells were mainly mononuclear and round or rod-shaped, contained different degrees of myofibrillar bundle organization, and exhibited nascent intercalated discs. These myofibrillar structures stained positively with anti human cardiac myosin heavy chain, anti  $\alpha$ -actinin, anti desmin, and anti cTnI mAbs. The cells, however, did not exhibit immunoreactivity with anti nebulin mAbs, a specific

skeletal muscle sarcomeric protein shown to be expressed early in skeletal myoblast differentiation (Begum, S. *et al.*, 1998. Cell Tissue Res. 293:305).

These results are consistent with ultrastructural properties of early stage cardiomyocytes and with the developmental process of myofibrillar assembly.

5 Previous studies demonstrated that during *in-vivo* cardiomyogenesis, myofibrils are initially distributed in sparse, irregular myofibrillar arrays, which gradually mature into parallel arrays of myofibrils and ultimately align into densely packed sarcomeres (Manasek, F.J., 1970. Am. J. Cardiol. 25:149, 22).

Embryonic stem cell-derived cardiomyocytic cells have previously been  
10 found to express a number of critical cardiomyocyte-specific genes, including those encoding the transcription factors GATA-4 and Nkx2.5 (Stainier D.Y.R., 2001. Nat Rev Gen. 2:39). In addition to these, the genes for the cardiac specific proteins atrial natriuretic peptide, cTnI, cTnT, MLC-2A, MLC-2V, and  $\alpha$ -myosin heavy chain were also found to be expressed in the embryonic stem cell-derived  
15 cardiomyocytic cells of the present invention. The presence of both MLC-2A and MLC-2V may suggest the presence of a number of cardiomyocytic cell types within the contracting areas.

The extracellular recordings, the  $[Ca^{2+}]_i$  transients, and the pharmacological studies clearly demonstrated that the contracting areas within  
20 the embryoid bodies displayed physiological properties consistent with cardiomyocytic tissue and significantly differed from noncardiac (skeletal or smooth) muscle. All components of normal cardiac excitation-contraction coupling were demonstrated within this tissue, namely electrical activation, increase in  $[Ca^{2+}]_i$  and the resulting contraction.

25 Little is known about calcium handling in the normal developing human heart. Intracellular calcium transients in adult human atrial tissue, studied using fura-2 (Brixius, K. *et al.*, 1997. J Appl Physiol. 83:652), were similar to the ones recorded in the present study with respect to total duration of the  $[Ca^{2+}]_i$  transient and to time of half-peak calcium relaxation. However, the time to peak transient  
30 in the embryoid bodies ( $130 \pm 27$  ms) was longer than the one obtained in human

atrial myocytes ( $52.5 \pm 3.1$  ms). This difference may have been the result of a number of causes. In the murine embryonic stem cell model, the contracting areas within embryoid bodies were shown to be a mixture of atrial, ventricular, and sinus nodal cells (Maltsev, VA. *Et al.*, 1993. *Mech Dev.* 44:41). Since  
5 different cardiomyocyte types display different calcium characteristics (Kolossoff E. *et al.*, 1998. *J Cell Biol.* 143:2045), it is possible that the  $[Ca^{2+}]_i$  transients measured in whole beating embryoid bodies, described in the present invention, represent a superposition of a mixed population of myocytes with fast and slow cell characteristics. Alternatively, the lower rate in  $[Ca^{2+}]_i$  elevation may reflect  
10 the suboptimal efficiency and immaturity of the calcium machinery in early developing cardiac cells.

The extracellular recordings demonstrated a sharp and a slow component, consistent with the relatively long action potential duration characteristic of cardiomyocytes. The positive and negative chronotropic responses to  
15 isoproterenol and carbamylcholine demonstrated the presence of functional adrenergic and cholinergic receptors, respectively, in pacemaker cells. A major pathway of the  $\beta$ -adrenoreceptor-dependent chronotropic response is the activation of adenylate cyclase and the consequent rise in cytosolic cAMP and stimulation of protein kinase. The positive chronotropic effect exerted by  
20 forskolin, a direct activator of adenylate cyclase, and by IBMX, a phosphodiesterase inhibitor, suggests that this signaling pathway is already present early in human cardiomyocytic differentiation.

There are numerous differences between human and mouse developing cardiomyocytes. In the normal embryo, heart formation begins with the initiation  
25 of differentiation by myocardial and endocardial precursors and leads up to the formation of the cardiac valves. These events cover the first 12 days in the life of a mouse embryo and the first 35 days in the life of a human embryo (Stainier, DYR., 2001. *Nat Rev Gen.* 2:39). It is not surprising, therefore, that differentiation of human embryonic stem cells into cardiomyocytes proceeds at a  
30 slower rate than in mouse embryonic stem cells. In mouse models, embryonic

stem cells are cultivated in hanging drops for 2 days, and further cultivated as embryoid bodies in suspension for 5 days. Spontaneously contracting areas appear 1 day postplating, and within 2–10 days 80–90 % of embryoid bodies reveal pulsating areas (Wobus, A.M. *et al.*, 1991. Differentiation 48:173). In the human embryonic stem cell differentiation system described herein, cells were grown in suspension for 10 days, and spontaneous contractions did not commence before day 4 postplating, with the median value being 11 days. Furthermore, only 8.1 % of embryoid bodies revealed pulsating areas. These variations may represent differences between the species, differences between the cell lines, or some yet undetermined factor required in the *in-vitro* differentiation of human embryonic stem cells. Several factors that may be optimized in the future in order to increase cardiomyocytic cell yield include different serum content, length of suspension period, the use of growth factors, or the use of supporting stroma.

Morphologically, *in-vitro* differentiation of human and mouse embryonic stem cells appears to follow parallel pathways. The assembly of the Z-line from periodically aligned Z-bodies and the transition from disorganized myofibrils to the more organized sarcomeric pattern described here have also been noted in the mouse model (Hescheler J. *et al.*, 1997. Cardiovasc Res. 36:149). In the two models, different degrees of myofibrillar assembly coexist within adjacent cardiomyocytic cells in the same embryoid body and within the same cell. Nevertheless, in the human model ultrastructural maturation proceeded much more slowly, seemed more heterogeneous, and did not reach the fully mature adult phenotype during the observation period.

**Conclusion:** These results therefore indicate that the present invention provides for the time a method of generating unlimited numbers of human cardiomyocytic cells, including developing cardiomyocytic cells. The cardiomyocytic cells of the present invention display a broad range of cardiac tissue specific structural and functional characteristics, including: rhythmic synchronous contraction; formation of sarcomeres, Z-bands, intercalated discs,

gap junctions, desmosomes and fibrillar bundles; expression of numerous cardiomyocyte specific, but not skeletal myocyte specific mRNAs and proteins; and cardiomyocyte specific electrophysiology, including cardiac specific chronotropic responses to pharmacological agents. Furthermore, the cardiomyocytic cells and tissues of the present invention display a sustained cardiomyocytic phenotype for at least 60 days *in-vitro*. Thus, the cardiomyocytic cells of the present invention are optimal, for example, for pharmacological and toxicological testing, functional genomics, early cardiomyogenesis, cell therapy, and tissue engineering. As such, the method of the present invention represents a dramatic and quantum improvement over all prior art methods of providing human cardiomyocytic cells.

## EXAMPLE 2

### *Generation of highly differentiated, highly functional human cardiomyocytic tissue via in-vitro culture of human embryonic stem cells*

The ability to generate human cardiac tissue *in-vitro* would be of enormous benefit for therapy of heart diseases, for testing the therapeutic and toxic effects of pharmacological and electrical treatments of human cardiac tissue, and for modeling aspects of the biology of human cardiac tissue, such as cardiac tissue development and cardiac tissue physiology. However, no prior art methods of generating human cardiac tissue *in-vitro* exist. Thus, in order to fulfill these important needs the present inventors have generated, for the first time, highly differentiated, highly functional human cardiomyocytic tissues by *in-vitro* culture of human embryonic stem cells, as follows.

#### *Materials and Methods:*

*Generation of human embryonic stem cell-derived cardiomyocytic cells and tissues:* Performed essentially as described in Example 1, hereinabove, for generation of human embryonic stem cell-derived cardiomyocytic cells. For generation of cardiomyocytic tissue, embryoid bodies were isolated at a stage of 24  $\pm$  9 days postplating (range, 12–54 days).



**Immunohistochemistry and confocal microscopy:** Embryoid bodies were fixed in 4 % paraformaldehyde and then blocked with PBS containing 1 % Triton X-100 and 2 % normal goat serum for 15 minutes at room temperature. Immunostaining was performed using anti cardiac troponin-I antibody (anti cTnI) at a dilution of 1:5000 and anti connexin43 antibody (anti Cx43) at a dilution of 1:100 in the blocking buffer for 24 hours at 4 °C. Preparations were then incubated with FITC-conjugated anti mouse and rhodamine-conjugated anti rabbit antibody at a dilution of 1:100 for 1 hour at room temperature (all antibodies from Chemicon, Temecula, CA). Confocal microscopy was performed using a Nikon Eclipse E600 microscope and Bio-Rad Radiance 2000 scanning system. These preparations were also used for morphometric studies in which the length, width, and length/width ratio of individual cultured human embryonic stem cell-derived cardiomyocytic cells were analyzed.

Quantitative analysis of the immunoreactive signal by confocal microscopy was performed as previously described (Saffitz JE. *et al.*, 2000. Am J Physiol Heart Circ Physiol. 278:H1662; Thomas SP. *et al.*, 2000. Circ Res. 87:467; Zhuang J. *et al.*, 2000. Circ Res. 87:316) with some modifications. Briefly, 3–5 high-power fields in each embryoid body studied were examined by fluorescence microscopy at a magnification of  $\times 60$ . Each test area, analyzed digitally, consisted of a matrix of  $512 \times 512$  pixels. The immunoreactive signal for anti Cx43 was concentrated as discrete spots of high-intensity signal along the cell membrane, allowing automatic detection of gap junctions by use of an arbitrary threshold value. The proportion of total cell area occupied by the Cx43 immunoreactive signal was defined as the percentage of high-intensity signal pixels divided by the total number of pixels in the field. The total number and average size of gap junction, identified as two or more contiguous high-intensity pixels ( $\geq 0.32 \mu\text{m}^2$ ), were also analyzed from the immunostained specimens.

**Multielectrode array mapping technique:** Extracellular electrophysiological recordings from the embryoid bodies were performed on a PC-based multielectrode array data acquisition system (Multi Channel Systems,

Reutlingen, Germany). The microelectrode array consisted of a  $50 \times 50$  mm glass substrate, in the center of which was an embedded  $1.4 \times 1.4$  mm matrix of 60 titanium nitride-gold contact ( $30 \mu\text{m}$ ) electrodes with an interelectrode distance of 100 or  $200 \mu\text{m}$  (Figure 7). This system allowed simultaneous recording of extracellular potentials from all electrodes for prolonged periods. Data were recorded at 10 kHz. During the recording sessions, the microelectrode array was constantly perfused with a gas mixture consisting of 5 %  $\text{CO}_2$  and 95 % air. Temperature was kept at  $37.0 \pm 0.1^\circ\text{C}$ .

Local activation time (LAT) at each electrode was determined, as previously described (Spach MS. & Dolber PC. 1986. Circ Res. 58:356), by the timing of the maximal negative intrinsic deflection ( $dV/dt_{\min}$ ) of the electrogram recorded at each electrode. The measured LATs at all electrodes were then used for the generation of color-coded activation maps by interpolating the local activation time values between the electrodes using the standard two dimensional plotting function of MATLAB software (MATLAB 5.3.0, The MathWorks, Natick, MA).

Local conduction velocity vector fields were estimated as previously described (Bayly PV. *et al.*, 1998. IEEE Trans Biomed Eng. 45:563), with some modifications. Briefly, each electrode was denoted by spatial and temporal (LAT) coordinates  $Z_i = [x, y, t]^T$ . Each sample point  $Z_i$  and its neighbors in each direction within a spatial window of  $\Delta x_{\max}$ ,  $\Delta y_{\max}$ , and temporal window of  $\Delta t_{\max}$  were fitted using a least-square algorithm to a second-degree polynomial surface. The fitting spatial window size was chosen to be five times interelectrode distance, and the temporal window was five times the total activation time. The velocity vectors of each point on the wave front,  $v = [dx/dt, dy/dt]^T$ , were derived from the fitted surface. Calculations and plotting were performed using MATLAB.

**Pharmacological analysis of conduction:** Following baseline recording,  $20 \mu\text{l}$  of stock solution of the test drug were added to the 2 ml of culture medium in the microelectrode array and stirred gently. The pharmacological agents used

included tetrodotoxin (TTX; Alomone Labs, Jerusalem, Israel) at a final concentration of 10  $\mu$ M, and diltiazem hydrochloride (1  $\mu$ M, Sigma Chemical Co., St. Louis, MO). Extracellular recordings were performed for 30 seconds, at baseline and 5 minutes following drug application. 1-Heptanol (at 0.3, 0.6, and 1 mM; Sigma) was dissolved in the medium by vigorous shaking, and extracellular recordings were performed immediately prior to and 30 minutes following the application of the drug.

The effects of these drugs on conduction were evaluated by examining possible changes in the culture's global velocity (measured as the distance between earliest and latest activation divided by the total microelectrode array activation time), in the mean magnitude of the local velocity vector, and in the maximal absolute value of the first time derivative of the extracellular signal

In order to study the effects of elevated extracellular potassium concentration on conduction properties, a baseline recording was performed in a modified Tyrode's solution (140 mM NaCl, 5.4 mM KCl, 10 mM glucose, 1 mM MgCl<sub>2</sub>, 2 mM pyruvate, 2 mM CaCl<sub>2</sub>, and 10 mM HEPES, titrated to pH 7.4 with NaOH). Extracellular recordings were then performed for 30 seconds, at baseline and 5 minutes after the solution was changed to three balanced high-concentration potassium solutions (10, 15, and 20 mM KCl).

**Statistical Analysis:** Values are mean  $\pm$  standard deviation. Changes in mean conduction velocity, local velocity vectors, and maximal absolute value of the first time derivative during elevation of the extracellular potassium were evaluated using Friedman's repeated measure ANOVA; comparisons with control were performed using Dunnett's method. Changes during tetrodotoxin, diltiazem, and 1-heptanol treatments were assessed using Wilcoxon signed rank test. Differences with a P value of  $< 0.05$  were considered statistically significant.

#### **Experimental Results:**

**Spontaneously contracting foci express cardiac troponin I and display gap junctions:** Spontaneously contracting human embryonic stem cell-derived

cardiomyocytic foci were identified in the outgrowth of the embryoid bodies. The diameter of these contracting foci varied between 0.3 and 2 mm. The contracting areas were mechanically dissected and assessed morphologically. Immunostaining with anti cTnI antibody (Figure 8a) demonstrated the presence of an isotropic tissue consisting of early-stage cardiomyocytic cells. In some of the embryoid bodies, more than one contracting area could be noted, usually connected through a narrow strand of cardiomyocytic tissue. The cardiomyocytic cells within the contracting areas were relatively small; mononuclear; round, triangular, or rod-shaped; and arranged in various orientations. The cells displayed variable degrees of sarcomeric organization, ranging from a relatively homogenous cytoplasmic staining to a more developed early-striated pattern. Average cell length and width were  $44.2 \pm 10.9$  and  $16.0 \pm 4.6$   $\mu\text{m}$ , respectively, with a mean length/width ratio of  $2.9 \pm 0.9$  ( $n = 67$ ).

The presence of gap junctions between the cells was demonstrated by the positive punctate staining with anti Cx43 antibody (Figure 8b). Figure 8c represent a typical confocal image of double immunostaining with anti cTnI antibody, identifying the embryonic stem cell-derived cardiomyocytic cells, and with anti Cx43 antibody, identifying the presence and spatial distribution of gap junctions. In all the preparations studied, the Cx43 immunoreactive signal appeared as high-intensity, relatively small, discrete spots, distributed homogeneously along the cell perimeter. The average size of an individual gap junction was  $0.49 \pm 0.28$   $\mu\text{m}^2$ . The number of gap junctions per 100  $\mu\text{m}^2$  was  $0.24 \pm 0.15$ , and the proportion of tissue area occupied by high-intensity immunoreactive signal was  $0.08 \pm 0.06$  %.

***High-resolution activation mapping of contractile cardiomyocytic foci:*** Spontaneously contracting areas of cardiomyocytic syncytia were mechanically dissected and cultured on microelectrode array plates (Figure 9a). This allowed long-term, high-resolution extracellular electrophysiological recordings from all 60 electrodes (Figure 9b). The signals were characterized by a sharp component, a return to baseline, and a slow component resembling the T wave.

The detailed activation maps constructed using these recordings demonstrated the development of a functional syncytium with synchronized action potential propagation. Figure 9c presents a typical activation map, with the propagation wave proceeding from the lower left corner to the top right corner of the microelectrode array and with a total activation time of 13 milliseconds. Impulse propagation can also be appreciated in the superimposed conduction velocity vectorial map.

Interestingly, both pacemaker position and conduction properties within each embryoid body were relatively reproducible during both short-term and long-term recordings. Thus, the average standard deviation of pacemaker position (identified by the site of earliest activation) was  $103 \pm 100 \mu\text{m}$  during relatively short-term (3-hour) recordings and was also relatively stable ( $264 \pm 146 \mu\text{m}$ ) during long-term recording (an average recording period of  $9.5 \pm 5.4$  days). Similarly, the average deviation in total activation time, global velocity (measured as the distance between earliest and latest activation divided by total activation time), and the mean magnitude of the local velocity vector were  $8 \pm 3$ ,  $8 \pm 5$ , and  $6 \pm 3 \%$ , respectively, during the short-term recordings and  $18 \pm 13$ ,  $20 \pm 8$ ,  $21 \pm 14 \%$ , respectively, during long-term recordings.

In contrast with the relatively reproducible measurements within each embryoid body, the conduction properties observed in different embryoid bodies were more heterogeneous. In general, two conduction types were noted. In the first type ( $n = 6$ ), a single, relatively broad area of cardiomyocytic tissue was present, resulting in relatively fast conduction (Figure 9c) throughout the measured area. This is also evident in the activation time histogram (Figure 9d), which demonstrates a single cluster of continuous activation times from early to late LATs. Total activation time in these embryoid bodies averaged  $10.3 \pm 3.8$  milliseconds, and the average magnitude of the local conduction velocity vector was  $14.2 \pm 9.5 \text{ cm/second}$ .

The second type of conduction was observed in embryoid bodies, in which a relatively narrow strand of conducting tissue interconnected two or more



contracting areas. A typical example is shown in the micrograph in Figure 10a, where the cardiomyocytic tissue is identified by immunostaining with anti cTnI antibody. The corresponding activation map recorded from this embryoid body is shown in Figure 10b. Note the presence of relatively fast activation within the two contracting areas (with very early or very late activation times), with significant time delay between them due to the narrow slow-conducting connecting strand. This can also be appreciated in the activation time histogram, which demonstrates the presence of very early or very late activated electrodes and paucity of electrodes with intermediate local activation time values (Figure 10c). This type of conduction pattern resulted in significant longer activation times ( $30.6 \pm 18.9$  milliseconds [ $n = 6$ ]) than in the first group ( $P < 0.05$ ) and in a lower magnitude of the average conduction velocity vector ( $4.4 \pm 2.9$  cm/second). Nevertheless, fast conduction was still present in the broader parts of these embryoid bodies.

*Pharmacologically induced slowing of conduction in human embryonic stem cell-derived cardiomyocytic cells:* The suitability of the cardiomyocyte electrophysiology model of the present invention for the study of slow conduction was assessed. It is well established that the three main mechanisms involved in conduction slowing are reduced excitability, reduced cell-to-cell coupling, and abnormalities in tissue architecture. Hence, by using different pharmacological strategies, slowing of conduction via each of these mechanisms was demonstrated, as follows.

Elevation of the extracellular potassium concentration was found to result in slowing of conduction, as manifested by an increase in total activation times from a baseline value of 25 milliseconds (in 5.3 mM potassium; Figure 11a) to values of 40, 70, and 120 milliseconds at extracellular potassium concentrations of 10, 15, and 20 mM, respectively (Figures 11b-d, respectively). Slowing of conduction during elevation of the extracellular potassium concentration was evident in all embryoid bodies studied ( $n = 7$ ; Table 2) by the significant decrease in global conduction velocity ( $P < 0.01$ ), in the mean magnitude of the

local velocity vector ( $P < 0.01$ ), and in the maximal absolute value of the first time derivative of the extracellular signal ( $-dV/dt_{\max}$ ,  $P < 0.01$ ).

Activation maps of the same embryoid body, during baseline and following application of 10  $\mu\text{M}$  of the fast sodium channel blocker tetrodotoxin (TTX) (Figures 12a-b, respectively) demonstrate slowing of conduction, as evidenced by the increase in the total microelectrode array activation time from a baseline value of 15 milliseconds to a value of 35 milliseconds. Blockade of the fast sodium channel resulted in slowing of conduction in all embryoid bodies, as manifested by the significant changes in all the electrophysiological parameters ( $n = 6$ ; Table 2) that were assessed. In contrast to these results, blockade of the L-type calcium channel by diltiazem (1  $\mu\text{M}$ ) did not result in significant changes in any of the parameters studied ( $n = 6$ ; Table 2).

**Table 2. Pharmacologically induced changes in conduction properties**

Treatment	Global Velocity (cm/sec)	Mean CV Vector (cm/sec)	Maximal -dv/dt (mV/sec)
Potassium – 5.4 mM	$2.1 \pm 1.0$	$4.1 \pm 4.1$	$3.1 \pm 6.4$
Potassium – 10 mM	$1.6 \pm 0.6^{\dagger}$	$3.5 \pm 4.2$	$2.7 \pm 5.5$
Potassium – 15 mM	$1.0 \pm 0.3^{\dagger}$	$2.0 \pm 2.3^{\dagger}$	$1.1 \pm 1.4$
Potassium – 20 mM	$1.0 \pm 0.4^{\dagger}$	$1.5 \pm 1^{\dagger}$	$1.1 \pm 1.2^{\dagger}$
TTX- Baseline	$3.2 \pm 2.7$	$5.1 \pm 6$	$2.1 \pm 2$
TTX – 10 $\mu\text{M}$	$1.8 \pm 0.9^*$	$3.2 \pm 3^{\dagger}$	$1.9 \pm 1.9^{\dagger}$
Diltiazem – Baseline	$2.8 \pm 1.9$	$6.0 \pm 8.2$	$2.3 \pm 2.6$
Diltiazem – 1 $\mu\text{M}$	$2.8 \pm 2.0$	$5.7 \pm 4.2$	$2.5 \pm 4.2$
Heptanol – Baseline	$2.1 \pm 0.9$	$4.3 \pm 5.3$	$2.8 \pm 3.1$
Heptanol – 0.3 mM	$1.7 \pm 0.6^*$	$3.0 \pm 5.7^{\dagger}$	$2.0 \pm 2.3^{\dagger}$
Heptanol – 0.6 mM	$1.2 \pm 0.9$	$3.0 \pm 3.8^{\dagger}$	$2.1 \pm 3.0^{\dagger}$
Heptanol – 1 mM	No conduction	No conduction	No conduction

\*  $p < 0.05$  or  $^{\dagger} p < 0.01$  when compared to baseline recordings.

15

Reduction of cell-to-cell coupling also resulted in slowing of conduction. Activation maps of the same embryoid body, during baseline and following application of 0.3 mM of 1-heptanol (Figures 13a-b, respectively) demonstrate an increase in total activation time from a baseline value of 15 milliseconds to a value of 32 milliseconds. The slowing of conduction by 0.3 mM of 1-heptanol was noted in all embryoid bodies studied ( $n = 7$ ; Table 2). Higher doses of 1-heptanol (0.6 and 1 mM) resulted in complete cessation of beating ( $n = 8$ ). In

20

four of the embryoid bodies, conduction was still maintained at 0.6 mM, but was significantly slower.

In a few preparations, the presence of strands of noncontracting tissue interspersed within the beating tissue were noted. These structural inhomogeneities resulted in the appearance of relatively slow conduction. One example can be seen in Figures 14a-b in which the presence of a noncontracting tissue resulted in alteration of the propagation pathway. The resulting activation wavefront curvature was associated with slowing of conduction, as can be appreciated by the long activation time (70 milliseconds) in this example.

10        *Analysis:*

*Structural properties:* The human embryonic stem cell-derived cardiomyocyte syncytia of the present invention were composed of one or a number of contracting foci connected by narrow strands, resulting in an inhomogeneous three dimensional aggregate of cardiomyocytic cells. While different from the two dimensional-patterned monolayers of neonatal rat and mouse cardiomyocytes used in other models, the pattern observed in this study was similar to the one described in the murine embryonic stem cell-derived cardiomyocytic model (Igelmund *et al.*, 1999. *Flugers Arch.* 437:669). The cardiomyocytic cells within the embryoid bodies varied in size and shape and were composed of relatively small, early-stage cardiomyocytic cells oriented in various directions. Again, this pattern was different from the above-mentioned patterned monolayers and from the adult human heart.

      This pattern of gap junction distribution was similar to the one observed by (Peters NS. *et al.*, 1994. *Circulation* 90:713) in human fetal and neonatal tissue, in which gap junctions and fascia adherens junctions in infantile ventricular tissue were distributed as small punctate spots of Cx43 and N-cadherin immunoreactive signals along the entire surface of the cells. The pattern of gap junction number, size, and distribution is an important determinant of conduction and has been shown to change in several physiological and pathological conditions (Saffitz JE. *et al.*, 2000. *Am J Physiol Heart Circ Physiol.*

278:H1662; Kanno S. and Saffitz JE. 2001. Cardiovasc Pathol. 10:169; Peters NS. *et al.*, 1997. Circulation 95:988; Peters NS. and Wit AL. 1998. Circulation 97:1746; Saffitz JE. *et al.*, 2000. Circ Res. 86:723; Saffitz JE. *et al.*, 1999. Cardiovasc Res. 42:309; Patel PM. *et al.*, 2001. J Cardiovasc Electrophysiol. 12:570).

**Conduction Properties:** The gross structural morphology of the cardiomyocytic tissue within the embryoid bodies had a significant effect on conduction properties. Significantly slower conduction velocities were observed in embryoid bodies in which narrow strands of conducting tissue interconnected two or more contracting areas relative to embryoid bodies containing a single, relatively broad area of cardiomyocytic tissue. A similar structural pattern was also described in a murine embryonic stem cell model (Igelmund P. *et al.*, 1999. Pflugers Arch. 437:669). Long-term electrophysiological recordings of the contracting embryoid bodies in that model demonstrated complex activity patterns due to intermittent blocks of action potential propagation in these narrow strands. Significantly, in the human model, these narrow bands, while significantly slowing conduction, did not cause similar conduction blocks.

The conduction velocity values observed in the current study, even in the relatively broad areas ( $14.2 \pm 9.5$  cm/second), were lower than the values reported in neonatal rat and mouse monolayers, which averaged 20–50 cm/second (Thomas SP. *et al.*, 2000. Circ Res. 87:467; Zhuang J. *et al.*, 2000. Circ Res. 87:316). The slower conduction observed here might have been the result of the relatively small cellular dimensions, the isotropic nature of the tissue, the heterogeneous distribution and lower density of the cells within the cellular network, and the lower gap junction size and density. It is important to note, however, that the measured velocity represents the two dimensional projection of the velocity vector within the three dimensional embryoid body.

Although significant differences in the conduction properties were noted between different embryoid bodies, most probably due to variability in the structural properties of the tissues, the electrophysiological parameters measured

within each embryoid body (pacemaker location and conduction velocity parameters) were reproducible during both short-term and long-term recordings. This is important since it allows assessing the effects of different pharmacological interventions as well as acute and long-term effects of remodeling processes using each embryoid body as its own control.

*Modeling of slow conduction:* The effects of reduction in excitability, decrement in cell-to-cell coupling, and alterations in tissue architecture, three key ingredients in the development of slow conduction (Rohr S. *et al.*, 1999. Trends Cardiovasc Med. 9:173; Rohr S. *et al.*, 1998. Circ Res. 83:781), an important factor associated with onset of cardiac arrhythmia were modeled using the method of the present invention. The results obtained were genetically consistent with the established role of these factors in the development of slow conduction. Analysis of the effects of decreased excitability on conduction using the fast sodium channel blocker TTX and elevation of extracellular potassium concentration demonstrated that depressed excitability resulted in a significant reduction in conduction velocity. The ability of TTX to decrease conduction and the absence of a similar effect by application of a selective calcium blocker demonstrated the presence and important role of the fast sodium current in impulse conduction within the embryonic stem cell-derived cardiomyocytic tissue during normal conduction. Nevertheless, persistence of conduction following TTX application (known to cause almost complete block of sodium channel at this concentration) and also during the presence of very high extracellular potassium concentration indicated that conduction, although significant slowed, could presumably be maintained under such conditions mainly via calcium channels. Similar results were obtained in a rat monolayer model (Rohr S. *et al.*, 1998. Circ Res. 83:781).

Reduction of cell-to-cell coupling induced by 1-heptanol administration also resulted in significant slowing of conduction, while higher doses of this agent resulted in conduction block. Significantly, the conduction velocity values obtained prior to the appearance of conduction block were not lower than those



observed following reduction of excitability. This is different from previous observations in the neonatal rat model (Rohr S. *et al.*, 1998. Circ Res. 83:781), which showed a higher safety factor for the uncoupling agents. This difference might have resulted from the limitation of the uncoupler used here, 1-heptanol, which may also affect several membrane currents. In addition to the above-mentioned mechanisms, we noted that alterations in tissue architecture also generated significant slowing of conduction. This was evidenced by the development of slow conduction in embryoid bodies containing narrow strands of conducting tissue, most probably due to sink-source mismatches. A similar slowing of conduction was noted in embryoid bodies in which the presence of nonconducting tissue resulted in significant curving of the activation wavefront.

**Conclusion:** These results therefore indicate that the present invention provides, for the first time, a means of generating an excitable human cardiac syncytium with synchronized action potential propagation. Such a syncytium can be used to investigate the structural and functional properties of cardiac tissue as well as to assess physiological and pathophysiological phenomena such as altered and slow conduction. The present invention furthermore provides, for the first time, a long-term human cardiomyocyte culture which can be used to study phenomena, such as cardiac electro-mechanical activity, on a long-term scale in cardiomyocytic tissue *in-vitro*. As such, the present invention is unique and far superior to all prior art methods of generating human cardiac tissue *in-vitro* suitable for treatment of cardiac diseases, testing the effect of compounds on cardiac cells and tissues, and for elucidation of cardiac tissue development and function.

25

### EXAMPLE 3

#### *Pacing of the ventricle in a complete heart block model using cardiomyocytic cells generated by cultured human embryonic stem cells*

Adult heart tissue has very poor regenerative capacity and therefore any significant cell loss or dysfunction of such tissue is essentially irreversible.

30

Many types of cardiac diseases, such as myocardial infarction, are associated with loss of cardiac tissue function, and may lead to the development of progressive heart failure. Tissue loss or dysfunction, occurring at critical sites in the conduction system of the heart, may also lead to inefficient rhythm initiation or impulse conduction. Consequentially, these processes may result in abnormally low heart rate (bradyarrhythmias) requiring the implantation of a permanent pacemaker. Cell therapy has been suggested as a novel therapy for restoration of the myocardial electromechanical functions. However, this approach is hampered by the lack of a human source for cardiac tissue, and by the absence of evidence for functional integration between host and donor tissue. The present inventors have therefore demonstrated the feasibility of using human embryonic stem cells to generate human cardiac tissue capable of restoring impaired cardiac function *in-vivo*, as follows.

***Materials and Methods:***

***Generation of human embryonic stem cell-derived cardiomyocytic cells and tissues:*** Performed as described above in Example 2 of the Examples section.

***Multielectrode array (MEA) extracellular electrophysiology mapping:*** Performed as described above in Example 2 of the Examples section.

***Optical-mechanical detection:*** Mechanical contractions were detected via microscope (Axiovert 135, Zeiss, Oberkochen, Germany) using a photodiode (UV100BG, EG&G, Vaudreuil, Canada). A 100-Watt Phillips projection lamp was used as a light source. Scattered light from the cultures was magnified with a 40× objective (Zeiss 440865). The emission field was limited to a contracting zone by placement of an adjustable rectangular diaphragm (Nikon Instruments Inc., Melville, New-York). The photodiode was positioned on top of a Microflex PFX (Nikon). The ocular finder was used for framing and focusing the framing the desired area of the specimen. Signals were filtered using a bidirectional Butterworth fourth order low-pass digital filter to obtain zero phase distortion with a cut-off frequency of 3 kHz.

*Generation of primary cardiomyocyte-human embryonic stem cell-derived cardiomyocytic hybrid tissue in-vitro:* Primary monolayer cultures of neonatal rat (Sprague Dawley) ventricular myocytes were prepared as previously described (Fast VG. and Kleber AG., 1993. Circ Res. 73:914). Briefly, following  
5 excision, the ventricles were minced and treated with RDB (IIBR, Ness-Ziona, Israel). Dispersed cells were then cultured on gelatin coated (0.1 %) microelectrode array plates or on glass cover slips at a density of  $1.5 \times 10^6$  cells/ml. Spontaneously contracting areas within human embryonic stem cell-derived embryoid bodies were mechanically dissected and grafted to the neonatal  
10 rat cultures once these displayed well synchronous activities (3–5 days postplating).

Pacing studies in co-cultures were performed by electrically stimulating the human or rat tissues with one of the electrodes of the multielectrode array.

*Immunohistochemistry:* Immunostaining of human cells and gap  
15 junctions in rat-human co-cultures was performed using anti human HLA class I (Dako, Copenhagen, Denmark), and anti connexin-43 (Cx43; Chemicon) as primary antibodies, respectively, and FITC-conjugated anti rabbit IgG and Cy-3-conjugated anti mouse IgG (Chemicon) as secondary antibodies. Analysis was performed via confocal microscopy (Nikon Eclipse E600) using a Bio-Rad  
20 Radiance 2000 scanning system. For identification of human cells in paraffin sections in transplantation studies (described hereinbelow), human embryoid bodies were labeled with the vital fluorescent lipophilic tracer CM-DiI (Molecular Probes) prior to grafting, and human cardiomyocytic cells were detected by primary anti cardiac troponin I (cTnI) and Cy-2 conjugated anti  
25 mouse IgG antibody.

*Lucifer yellow dye transfer:* In order to detect the presence of gap junctions between primary ventricular cardiomyocytes and cultured human embryonic stem cell-derived cardiomyocytic cells, rat cells growing in monolayer were dyed with lucifer yellow (ICN Biomedicals, Costa-Mesa, CA)  
30 prior to addition of human cells via scrape-loading with a pulled glass-pipette

following addition of lucifer yellow to a concentration of 0.025 %. The hybrid cultures were examined via confocal microscopy 24 hours following addition of the cultured human embryonic stem cell-derived cardiomyocytic cells. Lucifer yellow is a low-molecular weight dye that can pass through gap junctions.

5        *Transplantation of cultured human embryonic stem cell-derived cardiomyocytic cells into swine heart following atrioventricular block:* Seven domestic pigs (20–30 kg) were used in these studies, one of which died immediately following the initial procedure. The experimental protocol was approved by the Animal Study Committee of the Technion Faculty of Medicine.  
10        Anesthesia was induced with ketamine (10 mg/kg) and diazepam (1 mg/kg) intravenously and was maintained following intubation and mechanical ventilation with isofluorane 1 %. Vascular access was obtained using cutdown of the jugular veins and carotid arteries.

          A 7F locatable electrophysiological mapping catheter (Navistar, Boosense-Webster) was introduced under sterile conditions into the heart and  
15        was used to generate three dimensional electroanatomical maps of the heart using the Carto mapping technique. The catheter was then navigated to the His position (identified by the presence of clear His potential recording) and radiofrequency current was applied to generate complete atrioventricular block.  
20        A specially designed VVI pacemaker (ELA, France) was then implanted subcutaneously and its electrode was positioned at the RV apex to allow ventricular pacing in cases of decrease of ventricular rate to less than 50 beats/minute.

          The chest was then opened under sterile conditions by left thoracotomy  
25        through the fourth intercostal space, the pericardium was removed and cultured human embryonic stem cell-derived cardiomyocytic cells (20–40 contracting embryoid bodies, each embryoid body contains approximately 20,000 cells) or medium were injected into two different sites in the myocardium at the lateral and anterior walls respectively. A suture was used to mark the exact locations  
30        where injections were made. The human embryonic stem cell-derived tissue was

labeled prior to transplantation with the vital fluorescent lipophilic tracer CM-DiI (Molecular Probes), according to the manufacturer's instruction, to allow identification of the cells during the pathological examination.

Following the procedure, animals were treated with daily injections of cyclosporin A (15 mg/kg) and methylprednisolone (2 mg/kg) to prevent immune rejection. Body-surface ECG recordings were performed daily to characterize the rate and configuration of the escape rhythm.

One to three weeks posttransplant the animals were re-anesthetized, intubated and mechanically ventilated and detailed three dimensional electroanatomical maps of the (LV) were generated using the Carto three dimensional mapping technique. A catheter was navigated to the site of earliest activity identified on the map, and radiofrequency ablation was performed at a nearby position to allow pathological correlation with the maps.

Hematoxylin and eosin (H&E) staining was employed during pathological examination to visualize human cells engrafted within recipient cardiac tissue.

#### ***Experimental Results:***

***Functional integration of cultured human embryonic stem cell-derived cardiomyocytic cells with primary ventricular cardiomyocytes in-vitro:***  
Activation maps of spontaneously contracting areas of cultured human embryonic stem cell-derived cardiomyocytic cells plated onto microelectrode array plates demonstrated the development of an excitable medium with a stable pacemaker. Figure 15a presents a typical activation map, with the propagation wave proceeding from the lower left corner (earliest activation – red) to the top right corner (latest activation – blue), and with a total activation time of 13 milliseconds. The contraction of these embryoid bodies displayed positive chronotropic responses in the presence of 10  $\mu$ M isoproterenol (Figure 15b). Such cells were used to generate spontaneously and synchronously contracting hybrid primary ventricular-human embryonic stem cell-derived cardiomyocyte cultures on microelectrode array plates (Figure 16a). Significantly, synchronous contraction within the hybrid cultures was detected microscopically as soon as 24



hours postgrafting. Clearly identified synchronous contraction was observed in all 22 hybrid cultures studied. A typical microelectrode array activation map generated during spontaneous rhythmic contraction is shown in Figure 16b. Electrical activation initiated, in this case, within the rat tissue and then propagated to the rest of the hybrid culture, activating also the human tissue. Electrograms recorded simultaneously from the human and rat cardiomyocytic tissues (Figure 16c) demonstrated tight temporal coupling. This tight electrophysiological coupling was observed continuously for up to 21 days, the longest period studied. Long-term action-potential propagation between the two tissue types was also observed in pacing studies, in which either the rat (Figures 16d-e) or the human tissue (Figures 16f-g) was stimulated with an electrode.

In order to assess the presence of electromechanical coupling between the tissues, the contractions in the cultured human embryonic stem cell-derived cardiomyocytic cells, detected by a photodiode, were correlated with the electrical activity. As can be seen in Figure 16h the mechanical contractions detected in the human embryonic stem cell-derived cardiomyocytic cells were synchronous with the electrical activity in both the human and rat tissues.

The degree of electrical coupling was also assessed during long term recordings and during adrenergic stimulation. Isoproterenol (10  $\mu$ M) caused a significant increase in the spontaneous beating rate but electrical coupling between the human embryonic stem cell-derived and rat cardiomyocytic tissues was not hindered as can be appreciated in the cycle-length ratio histogram in Figure 16i.

***Abundant gap junction formation between cultured human embryonic stem cell-derived cardiomyocytic cells and primary ventricular cardiomyocytes:*** For electromechanical coupling to occur between primary cardiomyocytes and cultured human embryonic stem cell-derived cardiomyocytic cells, gap junctions must develop at the interface between these tissues. In order to detect such gap junctions, hybrid tissues were analyzed via immunofluorescent confocal microscopy for the presence of connexin-43, the major gap junction protein. The

human embryonic stem cell-derived tissue was identified by labeling the cells with anti human HLA class I antibody. The results demonstrate abundant expression of connexin-43 in the rat cardiomyocytes, in the cultured human embryonic stem cell-derived cardiomyocytic cells and at the junction between the two tissues (Figure 17a).

The presence of functional gap junctions was also demonstrated by the ability of lucifer yellow, which was scrape-loaded into the primary ventricular cardiomyocytes prior to grafting of human cells, to pass between the two cell types (Figure 17b).

*Restoration of impaired cardiac function in-vivo following transplantation of cultured human embryonic stem cell-derived cardiomyocytic cells:* To demonstrate functional integration of cultured human embryonic stem cell-derived cardiomyocytic cells in heart tissue *in-vivo*, a swine model of complete atrioventricular block was used. A typical ECG recording following the creation of atrioventricular block is shown in Figure 18a demonstrating complete atrioventricular dissociation with a typical nodal escape rhythm. In the initial days following creation of the atrioventricular block the nodal escape rhythm was occasionally very slow. In these cases episodes of overriding ventricular pacing originating from the VVI pacemaker occurred (Figure 18b).

Following creation of atrioventricular block, spontaneously contracting human embryoid bodies were injected into the posterolateral LV wall using an epicardial approach, and the location of the injection was marked with a suture. A control injection of medium in the anterior wall in each animal was also performed and its location was marked by a different suture.

Several days following cell transplantation, episodes of a ventricular rhythm different from that of nodal or paced rhythms were observed (Figure 18c). The morphology of the QRS of this new rhythm (negative axis in leads I, II, II) was completely different than that of nodal or paced rhythms, indicating its origin from a completely different focus. The average heart rate of this new rhythm was  $68 \pm 4$  beats/minute and was very similar to the swine's escape nodal

rhythm ( $65 \pm 2$  beats/minute) explaining the competition between the two rhythms. Significantly, the new rhythm was sensitive to catecholamines with the heart rate increasing to  $105 \pm 10$  beats/minute following administration of isoproterenol ( $20 \mu\text{M}$ ).

5 In order to determine whether this new rhythm originates from the pacemaking action of the transplanted cells, the animals were subjected to an additional electrophysiological mapping procedure one to three weeks (average: 12 days) following human embryonic stem cell-derived cardiomyocyte transplantation. Figures 19a-b show the anteroposterior (AP) view of two maps  
10 obtained during the two different rhythms. In Figure 19a, note the presence of earliest activation (red area) along the superior septum representing the origin of the nodal rhythm as identified immediately following generation of the complete atrioventricular block. In Figures 19c-d one can note that the earliest activation shifted from this area to the posterolateral wall during mapping of the new  
15 ventricular rhythm, two weeks following cell transplantation. This shift of the earliest activation site to the lateral wall can also be viewed on the left lateral view (Figure 19d, ).

In order to determine whether this new rhythm actually originated from the transplanted cells the catheter was navigated to the earliest activation site and  
20 a focal ablation was performed by applying radiofrequency energy at a site about 2 cm away from the earliest activation point. Figures 19e-f shows the pathological correlation in the same animal. In Figure 19e, note that the distance between the ablation site (marked by the pink needle) and the injection site (blue suture) was 2.1 cm. This distance was identical to the calculated distance  
25 between the ablation site (brown ball) and earliest activation site in the corresponding electroanatomical map (Figure 19f). These findings were consistent in all 4 animals in which radiofrequency current was delivered.

The survival of the grafted cells and their presence at the site of injection was verified during pathological examination. Figure 20a shows a  
30 hematoxylin and eosin (H&E) staining demonstrating the presence of the

transplanted human cardiomyocytic cells within the host myocardium at the site of injection. The transplanted human cardiomyocytic cells could also be identified by the fluorescent signal originating from the transplanted cells, which were labeled prior to transplantation with the vital fluorescent lipophilic tracer, CM-DiI (Figure 20b). The cardiomyocytic phenotype of the transplanted cells was verified by anti cTnI staining (Figure 20c). The presence of gap junctions between the transplanted and host cells could also be identified by staining with anti connexin 43 staining (Figure 20d). In contrast, sections taken from the control injection site or from distant areas of the ventricle did not show the presence of such cells. The presence of the transplanted cells was identified in all of the animals studied (n = 6).

**Conclusion:** These results demonstrate that the method of the present invention can be used to reproducibly derive cardiomyocytic cells from human embryonic stem cells having the capacity to form a cardiomyocytic syncytium displaying long term electromechanical activity, and that this tissue is able to form highly functional electromechanical connections with preexisting primary cardiac tissue whether *in-vitro* or *in-vivo*. Critically, when grafted *in-vivo* into heart tissue in a complete heart block model, the cultured human embryonic stem cell-derived cardiomyocytic cells of the present invention created functional connections and electrically activated the impaired host tissue. The method of the present invention is therefore unique and far superior to all prior art methods of providing embryonic stem cell derived human cardiac tissue suitable for transplantation and concomitant restitution of impaired cardiac function *in-vivo*.

25

#### EXAMPLE 4

##### ***Cardiomyocytic cells and tissues generated by in-vitro culture of human embryonic stem cells have the capacity to proliferate***

The extremely low capacity of adult cardiomyocytes to proliferate has to date represented an obstacle to approaches attempting to utilize *in-vitro* culture adult cardiomyocytes to generate cells and tissues suitable for repairing cardiac

30

tissue. Thus, methods of generating cardiomyocytic cells and tissues capable of significant proliferation would be of great biomedical benefit. In order to fulfill this important need, the present inventors have uncovered that culturing of human embryonic stem cells according to the method of the present invention  
5 can be used to generate cardiomyocytic cells and tissues capable of significant proliferation, as follows.

***Materials and Methods:***

***Generation of human embryonic stem cell-derived cardiomyocytic cells and tissues:*** Performed essentially as described in Example 2, hereinabove.

10 ***Proliferation assays:*** Proliferation was determined by  $^3\text{H}$ -thymidine uptake assay using autoradiography. Identification of cardiomyocytic cells was performed by staining cultures with anti  $\alpha$ -actinin antibodies.

***Experimental Results:***

15 A reproducible pattern of changes in the labeling index of embryonic stem cell derived cardiomyocytic cells, as assessed by  $^3\text{H}$ -thymidine labeling, was noted, as shown in Figures 20a-h. Analysis revealed that embryonic stem cells prior to initiation of cardiac differentiation were actively synthesizing DNA (labeling indices above 60 %; Figures 21a-b). A similar high labeling index was also noted in cardiomyocytic cells 7–20 days post plating with  $60 \pm 10$  % of the  
20 cells actively synthesizing DNA (10 days postplating—Figures 21c-d). The labelling index gradually declined at the stage 21–35 days post-plating ( $36 \pm 7$  %,  $p < 0.05$  compared to 7–20 days post plating; 30 days postplating—Figures 21e-f) and was reduced to less than 1 % after 36 days post-plating ( $p < 0.01$ ; 50 days postplating—Figures 21g-h).

25 ***Conclusion:*** Thus, the method of the present invention can be used to generate cultured human cardiomyocytic cells and tissues displaying significant capacity to proliferate for at least 35 days. The proliferative capacity of the cells and tissues of the present invention is unique relative to cells and tissues generated according to prior art methods, thus the cells and tissues of the present  
30 invention are optimal, for example, for therapeutic use in humans, notably for



repair of cardiac tissue, for testing the effects of compounds on cardiac specific cell and tissue growth *in-vitro*, and for studying aspects of cardiomyogenesis, such as cardiomyogenesis specific gene expression profiles.

5           Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. All publications, patents, patent  
10 applications and sequences identified by their accession numbers mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent, patent application or sequence identified by their accession number was specifically and individually indicated to be incorporated herein by reference. In addition,  
15 citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention.

## WHAT IS CLAIMED IS:

1. A method of generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype, the method comprising:
  - (a) partially dispersing a confluent cultured population of human stem cells, thereby generating a cell population including cell aggregates;
  - (b) subjecting said cell aggregates to culturing conditions suitable for generating embryoid bodies; and
  - (c) subjecting said embryoid bodies to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of said embryoid bodies, said culturing conditions suitable for inducing cardiac lineage differentiation including adherence of said embryoid bodies to a surface, thereby generating cells predominantly displaying at least one characteristic associated with the cardiac phenotype.
2. The method of claim 1, further comprising isolating said cell aggregates from said cell population prior to step (b).
3. The method of claim 1, further comprising isolating said embryoid bodies prior to step (c).
4. The method of claim 1, wherein said culturing conditions suitable for inducing cardiac lineage differentiation further include culture medium supplemented with serum.
5. The method of claim 1, further comprising screening and optionally isolating cells predominantly displaying at least one characteristic associated with a cardiac phenotype, said screening effected by at least one method selected from the group consisting of detection of mechanical

contraction, detection of a cardiac specific structure, detection of a cardiac specific protein, detection of a cardiac specific RNA, detection of cardiac specific electrical activity, detection of cardiac specific changes in the intracellular concentration of a physiological ion.

6. The method of claim 5, wherein said detection of cardiac specific electrical activity is effected using a microelectrode array.

7. The method of claim 6, wherein said multielectrode array comprises electrodes positioned 100  $\mu\text{m}$  or less apart.

8. The method of claim 6, wherein said multielectrode array comprises at least 60 electrodes.

9. The method of claim 6, wherein said multielectrode array is configured to obtain data characterizing said cardiac specific electrical activity with a frequency greater than a range selected from 1-25 kHz.

10. The method of claim 5, further comprising screening and optionally isolating cells substantially displaying proliferation.

11. The method of claim 1, wherein said human stem cells are embryonic stem cells.

12. The method of claim 1, wherein said human stem cells are clonal.

13. The method of claim 1, wherein said human stem cells are H9.2 cells.

14. The method of claim 1, wherein said partially dispersing a confluent cultured population of human stem cells is effected via a non-trypsin based method.

15. The method of claim 1, wherein said partially dispersing a confluent cultured population of human stem cells is effected via treatment with collagenase.

16. The method of claim 1, wherein said culturing in step (b) is effected for a time period selected from the range of 1 to 20 days.

17. The method of claim 1, wherein said culturing conditions in step (b) include inhibiting adherence of said cell aggregates to a surface.

18. The method of claim 1, wherein said culturing conditions in step (b) include culture medium supplemented with serum.

19. The method of claim 1, wherein said culturing in step (c) is effected for at least as long as a time period selected from the range of 1–60 days.

20. The method of claim 1, wherein said culturing in step (c) is effected in the presence of dimethyl sulfoxide.

21. The method of claim 1, wherein said culturing conditions in step (c) include exposing said embryoid bodies to a surface coated with gelatin.

22. The method of claim 1, wherein said at least one characteristic associated with a cardiac phenotype is selected from the group consisting of cardiac specific mechanical contraction, a cardiac specific structure, expression of a cardiac specific RNA, expression of a cardiac specific protein, cardiac

specific changes in the intracellular concentration of a physiological ion, cardiac specific electrical activity.

23. The method of claim 22, wherein said cardiac specific mechanical contraction is selected from the group consisting of spontaneous mechanical contraction, rhythmic mechanical contraction, synchronous mechanical contraction, and propagative mechanical contraction.

24. The method of claim 22, wherein said cardiac specific structure is selected from the group consisting of a sarcomere, a Z-band, an intercalated disc, a gap junction, a desmosome, a fibrillar bundle, a fibrillar bundle striation, and a myocytic syncytium.

25. The method of claim 22, wherein said cardiac specific RNA encodes a protein selected from the group consisting of cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain,  $\alpha$ -actinin, cardiac troponin I, cardiac troponin T, GATA-4, Nkx2.5, MLC-2A, MLC-2V, atrial myosin light chain, ventricular myosin light chain, and connexin-43.

26. The method of claim 22, wherein said cardiac specific protein is selected from the group consisting of cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain, atrial natriuretic peptide, cardiac troponin I, desmin and connexin-43.

27. The method of claim 22, wherein said cardiac specific electrical activity is selected from the group consisting of spontaneous electrical activity, rhythmic electrical activity, synchronized electrical activity, and propagative electrical activity.



28. The method of claim 27, wherein said propagative electrical activity is characterized by slow conduction.

29. A method of generating tissue predominantly displaying at least one characteristic associated with a cardiac phenotype, the method comprising:

- (a) partially dispersing a confluent cultured population of human stem cells, thereby generating a cell population including cell aggregates;
- (b) subjecting said cell aggregates to culturing conditions suitable for generating embryoid bodies; and
- (c) subjecting said embryoid bodies to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of said embryoid bodies, said culturing conditions suitable for inducing cardiac lineage differentiation including adherence of said embryoid bodies to a surface, thereby generating tissue predominantly displaying at least one characteristic associated with the cardiac phenotype.

30. The method of claim 29, further comprising isolating said cell aggregates from said cell population prior to step (b).

31. The method of claim 29, further comprising isolating said embryoid bodies prior to step (c).

32. The method of claim 29, wherein said culturing conditions suitable for inducing cardiac lineage differentiation further include culture medium supplemented with serum.

33. The method of claim 29, further comprising screening and optionally isolating tissue predominantly displaying at least one characteristic associated with a cardiac phenotype, said screening effected by at least one

method selected from the group consisting of detection of mechanical contraction, detection of a cardiac specific structure, detection of a cardiac specific protein, detection of a cardiac specific RNA, detection of cardiac specific electrical activity, and detection of cardiac specific changes in the intracellular concentration of a physiological ion.

34. The method of claim 33, wherein said detection of cardiac specific electrical activity is effected using a microelectrode array.

35. The method of claim 34, wherein said multielectrode array comprises electrodes positioned 100  $\mu\text{m}$  or less apart.

36. The method of claim 34, wherein said multielectrode array comprises at least 60 electrodes.

37. The method of claim 34, wherein said multielectrode array is configured to obtain data characterizing said cardiac specific electrical activity with a frequency greater than a range selected from 1-25 kHz.

38. The method of claim 33, further comprising screening and optionally isolating tissue substantially displaying proliferation.

39. The method of claim 29, wherein said human stem cells are embryonic stem cells.

40. The method of claim 29, wherein said human stem cells are clonal.

41. The method of claim 29, wherein said human stem cells are H9.2 cells.

42. The method of claim 29, wherein said partially dispersing a confluent cultured population of human stem cells is effected via a non-trypsin based method.

43. The method of claim 29, wherein said partially dispersing a confluent cultured population of human stem cells is effected via treatment with collagenase.

44. The method of claim 29, wherein said culturing in step (b) is effected for a time period selected from the range of 1 to 20 days.

45. The method of claim 29, wherein said culturing conditions in step (b) include inhibiting adherence of said cell aggregates to a surface.

46. The method of claim 29, wherein said culturing conditions in step (b) include culture medium supplemented with serum.

47. The method of claim 29, wherein said culturing in step (c) is effected for at least as long as a time period selected from the range of 1–60 days.

48. The method of claim 29, wherein said culturing in step (c) is effected in the presence of dimethyl sulfoxide.

49. The method of claim 29, wherein said culturing conditions in step (c) include exposing said embryoid bodies to a surface coated with gelatin.

50. The method of claim 29, wherein said at least one characteristic associated with a cardiac phenotype is selected from the group consisting of cardiac specific mechanical contraction, a cardiac specific structure, expression of a cardiac specific RNA, expression of a cardiac specific protein, cardiac

specific changes in the intracellular concentration of a physiological ion, and cardiac specific electrical activity.

51. The method of claim 50, wherein said cardiac specific mechanical contraction is selected from the group consisting of spontaneous mechanical contraction, rhythmic mechanical contraction, synchronous mechanical contraction, and propagative mechanical contraction.

52. The method of claim 50, wherein said cardiac specific structure is selected from the group consisting of a sarcomere, a Z-band, an intercalated disc, a gap junction, a desmosome, a fibrillar bundle, a fibrillar bundle striation, and a myocytic syncytium.

53. The method of claim 50, wherein said cardiac specific RNA encodes a protein selected from the group consisting of cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain,  $\alpha$ -actinin, cardiac troponin I, cardiac troponin T, GATA-4, Nkx2.5, MLC-2A, MLC-2V, atrial myosin light chain, ventricular myosin light chain, and connexin-43.

54. The method of claim 50, wherein said cardiac specific protein is selected from the group consisting of cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain, atrial natriuretic peptide, cardiac troponin I, desmin and connexin-43.

55. The method of claim 50, wherein said cardiac specific electrical activity is selected from the group consisting of spontaneous electrical activity, rhythmic electrical activity, synchronized electrical activity, and propagative electrical activity.

56. The method of claim 55, wherein said propagative electrical activity is characterized by slow conduction.

57. A method of characterizing a biological state or a biological process of cardiac cells or cardiac tissue, the method comprising:

- (a) partially dispersing a confluent cultured population of human stem cells, thereby generating a cell population including cell aggregates;
- (b) subjecting said cell aggregates to culturing conditions suitable for generating embryoid bodies;
- (c) subjecting said embryoid bodies to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of said embryoid bodies, said culturing conditions suitable for inducing cardiac lineage differentiation including adherence of said embryoid bodies to a surface, thereby generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or tissue predominantly displaying at least one characteristic associated with a cardiac phenotype; and
- (d) obtaining data characterizing the biological state or the biological process in said cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or said tissue predominantly displaying at least one characteristic associated with a cardiac phenotype.

58. The method of claim 57, further comprising isolating said cell aggregates from said cell population prior to step (b).

59. The method of claim 57, further comprising isolating said embryoid bodies prior to step (c).



60. The method of claim 57, wherein said culturing conditions suitable for inducing cardiac lineage differentiation further include culture medium supplemented with serum.

61. The method of claim 57, further comprising screening and optionally isolating cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or tissue predominantly displaying at least one characteristic associated with a cardiac phenotype, said screening effected by at least one method selected from the group consisting of detection of mechanical contraction, detection of a cardiac specific structure, detection of a cardiac specific protein, detection of a cardiac specific RNA, detection of cardiac specific electrical activity, and detection of cardiac specific changes in the intracellular concentration of a physiological ion.

62. The method of claim 61, wherein said detection of cardiac specific electrical activity is effected using a microelectrode array.

63. The method of claim 62, wherein said multielectrode array comprises electrodes positioned 100  $\mu\text{m}$  or less apart.

64. The method of claim 62, wherein said multielectrode array comprises at least 60 electrodes.

65. The method of claim 62, wherein said multielectrode array is configured to obtain data characterizing said cardiac specific electrical activity with a frequency greater than a range selected from 1-25 kHz.

66. The method of claim 61, further comprising screening and optionally isolating cells substantially displaying proliferation or tissue substantially displaying proliferation.

67. The method of claim 57, further comprising inducing the biological state or the biological process in said cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or said tissue predominantly displaying at least one characteristic associated with a cardiac phenotype.

68. The method of claim 67, wherein said inducing the biological state or the biological process is effected by treating said cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or said tissue predominantly displaying at least one characteristic associated with a cardiac phenotype with a treatment selected from the group consisting of a treatment with a drug, a treatment with a physiological ion, and an electrical treatment.

69. The method of claim 68, wherein said drug is selected from the group consisting of 1-heptanol, isoproterenol, carbamylcholine, forskolin, IBMX, atropine, tetrodotoxin, and diltiazem hydrochloride.

70. The method of claim 68, wherein said physiological ion is selected from the group consisting of a potassium ion, a sodium ion, and a calcium ion.

71. The method of claim 57, further comprising co-culturing said cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or said tissue predominantly displaying at least one characteristic associated with a cardiac phenotype with primary cardiac cells or primary cardiac tissue prior to step (d).

72. The method of claim 57, further comprising transplanting said cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or said tissue predominantly displaying at least one characteristic

associated with a cardiac phenotype into cardiac tissue of a recipient prior to step (d).

73. The method of claim 72, wherein said recipient is a swine.

74. The method of claim 57, wherein said human stem cells are embryonic stem cells.

75. The method of claim 57, wherein said human stem cells are clonal.

76. The method of claim 57, wherein said human stem cells are H9.2 cells.

77. The method of claim 57, wherein said partially dispersing a confluent cultured population of human stem cells is effected via a non-trypsin based method.

78. The method of claim 57, wherein said partially dispersing a confluent cultured population of human stem cells is effected via treatment with collagenase.

79. The method of claim 57, wherein said culturing in step (b) is effected for a time period selected from the range of 1 to 20 days.

80. The method of claim 57, wherein said culturing conditions in step (b) include inhibiting adherence of said cell aggregates to a surface.

81. The method of claim 57, wherein said culturing conditions in step (b) include culture medium supplemented with serum.

82. The method of claim 57, wherein said culturing in step (c) is effected for at least as long as a time period selected from the group consisting of 1–60 days.

83. The method of claim 57, wherein said culturing in step (c) is effected in the presence of dimethyl sulfoxide.

84. The method of claim 57, wherein said culturing conditions in step (c) include exposing said embryoid bodies to a surface coated with gelatin.

85. The method of claim 57, wherein said at least one characteristic associated with a cardiac phenotype is selected from the group consisting of cardiac specific mechanical contraction, a cardiac specific structure, expression of a cardiac specific RNA, expression of a cardiac specific protein, cardiac specific changes in the intracellular concentration of a physiological ion, and cardiac specific electrical activity.

86. The method of claim 85, wherein said cardiac specific mechanical contraction is selected from the group consisting of spontaneous mechanical contraction, rhythmic mechanical contraction, synchronous mechanical contraction, and propagative mechanical contraction.

87. The method of claim 85, wherein said cardiac specific structure is selected from the group consisting of a sarcomere, a Z-band, an intercalated disc, a gap junction, a desmosome, a fibrillar bundle, a fibrillar bundle striation, and a myocytic syncytium.

88. The method of claim 85, wherein said cardiac specific RNA encodes a protein selected from the group consisting of cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain,  $\alpha$ -actinin, cardiac troponin I, cardiac

troponin T, GATA-4, Nkx2.5, MLC-2A, MLC-2V, atrial myosin light chain, ventricular myosin light chain, and connexin-43.

89. The method of claim 85, wherein said cardiac specific protein is selected from the group consisting of cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain, atrial natriuretic peptide, cardiac troponin I, desmin and connexin-43.

90. The method of claim 85, wherein said cardiac specific electrical activity is selected from the group consisting of spontaneous electrical activity, rhythmic electrical activity, synchronized electrical activity, and propagative electrical activity.

91. The method of claim 90, wherein said propagative electrical activity is characterized by slow conduction.

92. The method of claim 57, wherein the biological state or the biological process is selected from the group consisting of cardiac specific mechanical contraction, a cardiac specific structure, expression of a cardiac specific RNA, expression of a cardiac specific protein, cardiac specific changes in the intracellular concentration of a physiological ion, cardiac specific electrical activity, and cardiomyogenesis.

93. The method of claim 92, wherein said cardiac specific mechanical contraction is selected from the group consisting of spontaneous mechanical contraction, rhythmic mechanical contraction, synchronous mechanical contraction, propagative mechanical contraction, and arrhythmic cardiac contraction.



94. The method of claim 92, wherein said cardiac specific structure is selected from the group consisting of a sarcomere, a Z-band, an intercalated disc, a gap junction, a desmosome, a fibrillar bundle, a fibrillar bundle striation, and a myocytic syncytium.

95. The method of claim 92, wherein said cardiac specific RNA encodes a protein selected from the group consisting of cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain,  $\alpha$ -actinin, cardiac troponin I, cardiac troponin T, GATA-4, Nkx2.5, MLC-2A, MLC-2V, atrial myosin light chain, ventricular myosin light chain, and connexin-43.

96. The method of claim 92, wherein said cardiac specific protein is selected from the group consisting of cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain, atrial natriuretic peptide, cardiac troponin I, desmin and connexin-43.

97. The method of claim 92, wherein said cardiac specific electrical activity is selected from the group consisting of spontaneous electrical activity, rhythmic electrical activity, synchronized electrical activity, and propagative electrical activity.

98. The method of claim 97, wherein said propagative electrical activity is characterized by slow conduction.

99. The method of claim 57, wherein the biological state or the biological process is cardiac specific electrical activity and whereas said obtaining data characterizing the biological state or the biological process is effected using a multielectrode array.

100. The method of claim 99, wherein said multielectrode array comprises electrodes positioned 100  $\mu\text{m}$  or less apart.

101. The method of claim 99, wherein said multielectrode array comprises at least 60 electrodes.

102. The method of claim 99, wherein said multielectrode array is configured to obtain data characterizing said cardiac specific electrical activity with a frequency greater than a range selected from 1-25 kHz.

103. A method of qualifying the effect of a treatment on a biological state or a biological process of cardiac cells or cardiac tissue, the method comprising:

- (a) partially dispersing a confluent cultured population of human stem cells, thereby generating a cell population including cell aggregates;
- (b) subjecting said cell aggregates to culturing conditions suitable for generating embryoid bodies;
- (c) subjecting said embryoid bodies to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of said embryoid bodies, said culturing conditions suitable for inducing cardiac lineage differentiation including adherence of said embryoid bodies to a surface, thereby generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or tissue predominantly displaying at least one characteristic associated with a cardiac phenotype;
- (d) subjecting said cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or said tissue predominantly displaying at least one characteristic associated with a cardiac phenotype to the treatment; and

- (e) monitoring the biological state or the biological process in said cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or said tissue predominantly displaying at least one characteristic associated with a cardiac phenotype, thereby qualifying the effect of the treatment on the biological state or the biological process.

104. The method of claim 103, wherein the treatment is effected by subjecting said cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or said tissue predominantly displaying at least one characteristic associated with a cardiac phenotype to an exposure to a compound or to an electrical treatment.

105. The method of claim 103, further comprising isolating said cell aggregates from said cell population prior to step (b).

106. The method of claim 103, further comprising isolating said embryoid bodies prior to step (c).

107. The method of claim 103, wherein said culturing conditions suitable for inducing cardiac lineage differentiation further include culture medium supplemented with serum.

108. The method of claim 103, further comprising screening and optionally isolating cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or tissue predominantly displaying at least one characteristic associated with a cardiac phenotype, said screening effected by at least one method selected from the group consisting of detection of mechanical contraction, detection of a cardiac specific structure, detection of a cardiac specific protein, detection of a cardiac specific RNA, detection of cardiac

specific electrical activity, and detection of cardiac specific changes in the intracellular concentration of a physiological ion.

109. The method of claim 108, further comprising screening and optionally isolating cells substantially displaying proliferation or tissue substantially displaying proliferation.

110. The method of claim 103, further comprising inducing the biological state or the biological process in said cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or said tissue predominantly displaying at least one characteristic associated with a cardiac phenotype.

111. The method of claim 110, wherein said inducing the biological state or the biological process is effected by treating said cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or said tissue predominantly displaying at least one characteristic associated with a cardiac phenotype with a treatment selected from the group consisting of a treatment with a drug, a treatment with a physiological ion, and an electrical treatment.

112. The method of claim 111, wherein said drug is selected from the group consisting of 1-heptanol, isoproterenol, carbamylcholine, forskolin, IBMX, atropine, tetrodotoxin, and diltiazem hydrochloride.

113. The method of claim 111, wherein said physiological ion is selected from the group consisting of a potassium ion, a sodium ion, and a calcium ion.

114. The method of claim 103, further comprising co-culturing said cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or said tissue predominantly displaying at least one characteristic associated with a cardiac phenotype with primary cardiac cells or primary cardiac tissue following step (c).

115. The method of claim 103, further comprising transplanting said cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or said tissue predominantly displaying at least one characteristic associated with a cardiac phenotype into cardiac tissue of a recipient following step (c).

116. The method of claim 115, wherein said recipient is a swine.

117. The method of claim 103, wherein said human stem cells are embryonic stem cells.

118. The method of claim 103, wherein said human stem cells are clonal.

119. The method of claim 103, wherein said human stem cells are H9.2 cells.

120. The method of claim 103, wherein said partially dispersing a confluent cultured population of human stem cells is effected via a non-trypsin based method.

121. The method of claim 103, wherein said partially dispersing a confluent cultured population of human stem cells is effected via treatment with collagenase.



122. The method of claim 103, wherein said culturing in step (b) is effected for a time period selected from the range of 1 to 20 days.

123. The method of claim 103, wherein said culturing conditions in step (b) include inhibiting adherence of said cell aggregates to a surface.

124. The method of claim 103, wherein said culturing conditions in step (b) include culture medium supplemented with serum.

125. The method of claim 103, wherein said culturing in step (c) is effected for at least as long as a time period selected from the range of 1–60 days.

126. The method of claim 103, wherein said culturing in step (c) is effected in the presence of dimethyl sulfoxide.

127. The method of claim 103, wherein said culturing conditions in step (c) include exposing said embryoid bodies to a surface coated with gelatin.

128. The method of claim 103, wherein said at least one characteristic associated with a cardiac phenotype is selected from the group consisting of cardiac specific mechanical contraction, a cardiac specific structure, expression of a cardiac specific RNA, expression of a cardiac specific protein, cardiac specific changes in the intracellular concentration of a physiological ion, and cardiac specific electrical activity.

129. The method of claim 128, wherein said cardiac specific mechanical contraction is selected from the group consisting of spontaneous mechanical contraction, rhythmic mechanical contraction, synchronous mechanical contraction, and propagative mechanical contraction.

130. The method of claim 128, wherein said cardiac specific structure is selected from the group consisting of a sarcomere, a Z-band, an intercalated disc, a gap junction, a desmosome, a fibrillar bundle, a fibrillar bundle striation, and a myocytic syncytium.

131. The method of claim 128, wherein said cardiac specific RNA encodes a protein selected from the group consisting of cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain,  $\alpha$ -actinin, cardiac troponin I, cardiac troponin T, GATA-4, Nkx2.5, MLC-2A, MLC-2V, atrial myosin light chain, ventricular myosin light chain, and connexin-43.

132. The method of claim 128, wherein said cardiac specific protein is selected from the group consisting of cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain, atrial natriuretic peptide, cardiac troponin I, desmin and connexin-43.

133. The method of claim 128, wherein said cardiac specific electrical activity is selected from the group consisting of spontaneous electrical activity, rhythmic electrical activity, synchronized electrical activity, and propagative electrical activity.

134. The method of claim 133, wherein said propagative electrical activity is characterized by slow conduction.

135. The method of claim 103, wherein the biological state or the biological process is selected from the group consisting of cardiac specific mechanical contraction, a cardiac specific structure, expression of a cardiac specific RNA, expression of a cardiac specific protein, cardiac specific changes in the intracellular concentration of a physiological ion, cardiac specific electrical activity, and cardiomyogenesis.

136. The method of claim 135, wherein said cardiac specific mechanical contraction is selected from the group consisting of spontaneous mechanical contraction, rhythmic mechanical contraction, synchronous mechanical contraction, propagative mechanical contraction, and arrhythmic cardiac contraction.

137. The method of claim 135, wherein said cardiac specific structure is selected from the group consisting of a sarcomere, a Z-band, an intercalated disc, a gap junction, a desmosome, a fibrillar bundle, a fibrillar bundle striation, and a myocytic syncytium.

138. The method of claim 135, wherein said cardiac specific RNA encodes a protein selected from the group consisting of cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain,  $\alpha$ -actinin, cardiac troponin I, cardiac troponin T, GATA-4, Nkx2.5, MLC-2A, MLC-2V, atrial myosin light chain, ventricular myosin light chain, and connexin-43.

139. The method of claim 135, wherein said cardiac specific protein is selected from the group consisting of cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain, atrial natriuretic peptide, cardiac troponin I, desmin and connexin-43.

140. The method of claim 135, wherein said cardiac specific electrical activity is selected from the group consisting of spontaneous electrical activity, rhythmic electrical activity, synchronized electrical activity, and propagative electrical activity.

141. The method of claim 140, wherein said propagative electrical activity is characterized by slow conduction.

142. The method of claim 103, wherein the biological state or the biological process is cardiac specific electrical activity and whereas said monitoring the biological state or the biological process is effected using a multielectrode array.

143. The method of claim 142, wherein said multielectrode array comprises electrodes positioned 100  $\mu\text{m}$  or less apart.

144. The method of claim 142, wherein said multielectrode array comprises at least 60 electrodes.

145. The method of claim 142, wherein said multielectrode array is configured to obtain data characterizing said cardiac specific electrical activity with a frequency greater than a range selected from 1-25 kHz.

146. A method of repairing cardiac tissue in a subject, the method comprising:

- (a) partially dispersing a confluent cultured population of human stem cells, thereby generating a cell population including cell aggregates;
- (b) subjecting said cell aggregates to culturing conditions suitable for generating embryoid bodies;
- (c) subjecting said embryoid bodies to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of said embryoid bodies, said culturing conditions suitable for inducing cardiac lineage differentiation including adherence of said embryoid bodies to a surface, thereby generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or tissue predominantly displaying at least one characteristic associated with a cardiac phenotype; and

- (d) administering a therapeutically effective dose of said cells predominantly displaying at least one characteristic associated with a cardiac phenotype, and/or said tissue predominantly displaying at least one characteristic associated with a cardiac phenotype to the heart of the subject, thereby repairing cardiac tissue in the subject.

147. The method of claim 146, further comprising isolating said cell aggregates from said cell population prior to step (b).

148. The method of claim 146, further comprising isolating said embryoid bodies prior to step (c).

149. The method of claim 146, wherein said culturing conditions suitable for inducing cardiac lineage differentiation further include culture medium supplemented with serum.

150. The method of claim 146, further comprising screening and optionally isolating cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or tissue predominantly displaying at least one characteristic associated with a cardiac phenotype, said screening effected by at least one method selected from the group consisting of detection of mechanical contraction, detection of a cardiac specific structure, detection of a cardiac specific protein, detection of a cardiac specific RNA, detection of cardiac specific electrical activity, and detection of cardiac specific changes in the concentration of intracellular calcium ion.

151. The method of claim 5, wherein said detection of cardiac specific electrical activity is effected using a microelectrode array.



152. The method of claim 151, wherein said multielectrode array comprises electrodes positioned 100  $\mu\text{m}$  or less apart.

153. The method of claim 151, wherein said multielectrode array comprises at least 60 electrodes.

154. The method of claim 151, wherein said multielectrode array is configured to obtain data characterizing said cardiac specific electrical activity with a frequency greater than a range selected from 1-25 kHz.

155. The method of claim 150, further comprising screening and optionally isolating cells substantially displaying proliferation or tissue substantially displaying proliferation.

156. The method of claim 146, further comprising treating the subject with an immunosuppressive regimen, thereby promoting engraftment of said cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or said tissue predominantly displaying at least one characteristic associated with a cardiac phenotype in the subject.

157. The method of claim 146, wherein said administering is effected by injection of said cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or said tissue predominantly displaying at least one characteristic associated with a cardiac phenotype into the heart of the subject.

158. The method of claim 146, further comprising inactivating or removing pathogenic cardiac cells or cardiac tissue in the subject

159. The method of claim 146, wherein said human stem cells are embryonic stem cells.

160. The method of claim 146, wherein said human stem cells are clonal.

161. The method of claim 146, wherein said human stem cells are H9.2 cells.

162. The method of claim 146, wherein said human stem cells are syngeneic with the subject.

163. The method of claim 146, wherein said partially dispersing a confluent cultured population of human stem cells is effected via a non-trypsin based method.

164. The method of claim 146, wherein said partially dispersing a confluent cultured population of human stem cells is effected via treatment with collagenase.

165. The method of claim 146, wherein said culturing in step (b) is effected for a time period selected from the range of 1 to 20 days.

166. The method of claim 146, wherein said culturing conditions in step (b) include inhibiting adherence of said cell aggregates to a surface.

167. The method of claim 146, wherein said culturing conditions in step (b) include culture medium supplemented with serum.

168. The method of claim 146, wherein said culturing in step (c) is effected for at least as long as a time period selected from the range of 1–60 days.

169. The method of claim 146, wherein said culturing in step (c) is effected in the presence of dimethyl sulfoxide.

170. The method of claim 146, wherein said culturing conditions in step (c) include exposing said embryoid bodies to a surface coated with gelatin.

171. The method of claim 146, wherein said at least one characteristic associated with a cardiac phenotype is selected from the group consisting of cardiac specific mechanical contraction, a cardiac specific structure, expression of a cardiac specific RNA, expression of a cardiac specific protein, cardiac specific changes in the intracellular concentration of a physiological ion, and cardiac specific electrical activity.

172. The method of claim 171, wherein said cardiac specific mechanical contraction is selected from the group consisting of spontaneous mechanical contraction, rhythmic mechanical contraction, synchronous mechanical contraction, and propagative mechanical contraction.

173. The method of claim 171, wherein said cardiac specific structure is selected from the group consisting of a sarcomere, a Z-band, an intercalated disc, a gap junction, a desmosome, a fibrillar bundle, a fibrillar bundle striation, and a myocytic syncytium.

174. The method of claim 171, wherein said cardiac specific RNA encodes a protein selected from the group consisting of cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain,  $\alpha$ -actinin, cardiac troponin I, cardiac troponin T, GATA-4, Nkx2.5, MLC-2A, MLC-2V, atrial myosin light chain, ventricular myosin light chain, and connexin-43.

175. The method of claim 171, wherein said cardiac specific protein is selected from the group consisting of cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain, atrial natriuretic peptide, cardiac troponin I, desmin and connexin-43.

176. The method of claim 171, wherein said cardiac specific electrical activity is selected from the group consisting of spontaneous electrical activity, rhythmic electrical activity, synchronized electrical activity, and propagative electrical activity.

177. The method of claim 146, wherein the subject is a human or a nonhuman mammal.

178. The method of claim 146, wherein the subject has a cardiac disorder characterized by cardiac arrhythmia, and whereas said administering is effected by intra-myocardial injection of said cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or said tissue predominantly displaying at least one characteristic associated with a cardiac phenotype, thereby treating said disorder characterized by cardiac arrhythmia.

179. The method of claim 146, wherein the subject has a cardiac disorder characterized by myocardial ischemia, and whereas said administering is effected by intra-myocardial injection of said cells predominantly displaying at least one characteristic associated with a cardiac phenotype, or said tissue predominantly displaying at least one characteristic associated with a cardiac phenotype, thereby treating said disorder characterized by myocardial ischemia.

180. An *in-vitro* culture of isolated human cells which will display substantial proliferation for at least as long as a time period selected from the range of 1–35 days, and which will predominantly display at least one

characteristic associated with a cardiac phenotype for at least as long as a time period selected from the range of 1–60 days.

181. The *in-vitro* culture of claim 180, wherein said at least one characteristic associated with a cardiac phenotype is selected from the group consisting of mechanical contraction, a cardiac specific structure, a cardiac specific protein, a cardiac specific RNA, cardiac specific electrical activity, cardiac specific changes in the intracellular concentration of a physiological ion, and cardiomyogenesis.

182. The *in-vitro* culture of claim 181, wherein said isolated human cells are cultured in contact with a multielectrode array configured for monitoring said cardiac specific electrical activity.

183. The method of claim 182, wherein said multielectrode array comprises electrodes positioned 100  $\mu\text{m}$  or less apart.

184. The method of claim 182, wherein said multielectrode array comprises at least 60 electrodes.

185. The method of claim 182, wherein said multielectrode array is configured to obtain data characterizing said cardiac specific electrical activity with a frequency greater than a range selected from 1-25 kHz.

186. The *in-vitro* culture of claim 181, wherein said cardiac specific mechanical contraction is selected from the group consisting of spontaneous mechanical contraction, rhythmic mechanical contraction, synchronous mechanical contraction, and propagative mechanical contraction.

187. The *in-vitro* culture of claim 181, wherein said cardiac specific structure is selected from the group consisting of a sarcomere, a Z-band, an intercalated disc, a gap junction, a desmosome, a fibrillar bundle, a fibrillar bundle striation, and a myocytic syncytium.

188. The *in-vitro* culture of claim 181, wherein said cardiac specific RNA encodes a protein selected from the group consisting of cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain,  $\alpha$ -actinin, cardiac troponin I, cardiac troponin T, GATA-4, Nkx2.5, MLC-2A, MLC-2V, atrial myosin light chain, ventricular myosin light chain, and connexin-43.

189. The *in-vitro* culture of claim 181, wherein said cardiac specific protein is selected from the group consisting of cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain, atrial natriuretic peptide, cardiac troponin I, desmin and connexin-43.

190. The *in-vitro* culture of claim 181, wherein said cardiac specific electrical activity is selected from the group consisting of spontaneous electrical activity, rhythmic electrical activity, synchronized electrical activity, and propagative electrical activity.

191. The *in-vitro* culture of claim 190, wherein said propagative electrical activity is characterized by slow conduction.

192. The *in-vitro* culture of claim 181, wherein said isolated human cells essentially have a genotype of H9.2 cells.

193. An *in-vitro* culture of an isolated human tissue comprising cells displaying at least one characteristic associated with a cardiac phenotype, said cells being capable of proliferating in culture for at least 35 days.



194. The *in-vitro* culture of claim 193, wherein said at least one characteristic associated with a cardiac phenotype is selected from the group consisting of mechanical contraction, a cardiac specific structure, a cardiac specific protein, a cardiac specific RNA, cardiac specific electrical activity, cardiac specific changes in the intracellular concentration of a physiological ion, and cardiomyogenesis.

195. The *in-vitro* culture of claim 194, wherein said cardiac specific mechanical contraction is selected from the group consisting of spontaneous mechanical contraction, rhythmic mechanical contraction, synchronous mechanical contraction, and propagative mechanical contraction.

196. The *in-vitro* culture of claim 194, wherein said cardiac specific structure is selected from the group consisting of a sarcomere, a Z-band, an intercalated disc, a gap junction, a desmosome, a fibrillar bundle, a fibrillar bundle striation, and a myocytic syncytium.

197. The *in-vitro* culture of claim 194, wherein said cardiac specific RNA encodes a protein selected from the group consisting of cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain,  $\alpha$ -actinin, cardiac troponin I, cardiac troponin T, GATA-4, Nkx2.5, MLC-2A, MLC-2V, atrial myosin light chain, ventricular myosin light chain, and connexin-43.

198. The *in-vitro* culture of claim 194, wherein said cardiac specific protein is selected from the group consisting of cardiac  $\alpha$ -myosin heavy chain, cardiac  $\beta$ -myosin heavy chain, atrial natriuretic peptide, cardiac troponin I, desmin and connexin-43.

199. The *in-vitro* culture of claim 194, wherein said cardiac specific electrical activity is selected from the group consisting of spontaneous electrical

activity, rhythmic electrical activity, synchronized electrical activity, and propagative electrical activity.

200. The *in-vitro* culture of claim 199, wherein said propagative electrical activity is characterized by slow conduction.

201. The *in-vitro* culture of claim 194, wherein the isolated human tissue essentially has a genotype of H9.2 cells.




Fig. 1a

Fig. 1b

Fig. 1c

Fig. 1d





Fig. 2




Fig. 3a




Fig. 3b



Fig. 3c



Fig. 3d



Fig. 3e

3/18



Fig. 4a




Fig. 4d




Fig. 4b




Fig. 4e




Fig. 4c




Fig. 4f

4/18




Fig. 5




Fig. 6a




Fig. 6b



5/18




Fig. 6c








Fig. 7



7/18



Fig. 10a




Fig. 10b




Fig. 10c



8/18




Fig. 11a




Fig. 11b




Fig. 11c




Fig. 11d

9/18




Fig. 12a




Fig. 12b




Fig. 13a




Fig. 13b

10/18




Fig. 14a




Fig. 14b



11/18




Fig. 15a




Fig. 15b




Fig. 16a

12/18




Fig. 16b




Fig. 16c




Fig. 16d




Fig. 16e




Fig. 16f




Fig. 16g

13/18




Fig. 16h




Fig. 16i

14/18




Fig. 17a




Fig. 17b

15/18




Fig. 18a




Fig. 18b




Fig. 18c



16/18




Fig. 19a




Fig. 19b




Fig. 19c




Fig. 19d




Fig. 19e




Fig. 19f






Fig. 20a




Fig. 20b



Fig. 20c



Fig. 20d



Fig. 21a

Fig. 21b




Fig. 21c

Fig. 21d



Fig. 21e

Fig. 21f




Fig. 21g

Fig. 21h

SEQUENCE LISTING

<110> Gepstein, Lior

Kehat, Itzhak

Itskovitz-Eldar, Joseph

Amit, Michal

<120> METHODS OF GENERATING HUMAN CARDIAC CELLS AND TISSUES AND USES THEREOF

<130> 02/23906

<160> 20

<170> PatentIn version 3.1

<210> 1

<211> 22

<212> DNA

<213> Artificial sequence

<220>

<223> Single strand DNA oligonucleotide

<400> 1

gaaccagagg ggagagacag ag

22

<210> 2

<211> 22

<212> DNA

<213> Artificial sequence

2

&lt;220&gt;

&lt;223&gt; Single strand DNA oligonucleotide

&lt;400&gt; 2

ccctcagctt gcttttttagg ag

22

&lt;210&gt; 3

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Single strand DNA oligonucleotide

&lt;400&gt; 3

acagagttta ttgaggtgcc cc

22

&lt;210&gt; 4

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Single strand DNA oligonucleotide

&lt;400&gt; 4

aaggtgaagt gtcccagagg

20

&lt;210&gt; 5

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Single strand DNA oligonucleotide

&lt;400&gt; 5

tattggaaca tggcctctgg at

22

<210> 6

<211> 22

<212> DNA

<213> Artificial sequence

<220>

<223> Single strand DNA oligonucleotide

<400> 6

ggtgctgaag gctgattacg tt

22

<210> 7

<211> 22

<212> DNA

<213> Artificial sequence

<220>

<223> Single strand DNA oligonucleotide

<400> 7

agacatcgca ctgactgaga ac

22

<210> 8

<211> 22

<212> DNA

<213> Artificial sequence

<220>

<223> Single strand DNA oligonucleotide

<400> 8

gacgggtcac tatctgtgca ac

22

<210> 9

<211> 22

<212> DNA

<213> Artificial sequence

<220>

<223> Single strand DNA oligonucleotide

<400> 9

gtcattgctg aaaccgagaa tg

22

<210> 10

<211> 22

<212> DNA

<213> Artificial sequence

<220>

<223> Single strand DNA oligonucleotide

<400> 10

gcaaagtact ggatgacacg ct

22

<210> 11

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> Single strand DNA oligonucleotide

<400> 11

gagaacaatg agaaccttca ggaga

25

<210> 12

<211> 23

<212> DNA

<213> Artificial sequence



<220>		
<223>	Single strand DNA oligonucleotide	
<400>	12	
	ttctggcgcc ggttacagaa cca	23
<210>	13	
<211>	20	
<212>	DNA	
<213>	Artificial sequence	
<220>		
<223>	Single strand DNA oligonucleotide	
<400>	13	
	cttcaagcca gaggcctacg	20
<210>	14	
<211>	20	
<212>	DNA	
<213>	Artificial sequence	
<220>		
<223>	Single strand DNA oligonucleotide	
<400>	14	
	ccgcctctgt cttcttcagc	20
<210>	15	
<211>	22	
<212>	DNA	
<213>	Artificial sequence	
<220>		
<223>	Single strand DNA oligonucleotide	
<400>	15	
	ggcagcggaa gaggatgctg aa	22

<210> 16

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> Single strand DNA oligonucleotide

<400> 16

gaggcaccaa gttgggcatg aacga

25

<210> 17

<211> 22

<212> DNA

<213> Artificial sequence

<220>

<223> Single strand DNA oligonucleotide

<400> 17

ccctgcacca gcccgaatca ga

22

<210> 18

<211> 21

<212> DNA

<213> Artificial sequence

<220>

<223> Single strand DNA oligonucleotide

<400> 18

cgaagcccag cccggtcaac t

21

<210> 19

<211> 20

<212> DNA  
<213> Artificial sequence

<220>  
<223> Single strand DNA oligonucleotide  
<400> 19  
agccacatcg ctcagacacc

20

<210> 20  
<211> 20  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Single strand DNA oligonucleotide  
<400> 20  
gtactcagcg gccagcatcg

20

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
30 January 2003 (30.01.2003)

PCT

(10) International Publication Number  
**WO 03/008535 A3**

(51) International Patent Classification<sup>7</sup>: C12Q 1/02,  
C12N 5/00, 5/02, 5/08, A01N 63/00, A61K 48/00

(21) International Application Number: PCT/IL02/00606

(22) International Filing Date: 21 July 2002 (21.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/306,462 20 July 2001 (20.07.2001) US

(71) Applicant (for all designated States except US): **TECH-  
NION RESEARCH AND DEVELOPMENT FOUN-  
DATION LTD.** [IL/IL]; Senate House, Technion City, 32  
000 Haifa (IL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GEPSTEIN, Lior**  
[IL/IL]; 26 Raanan Street, 34 384 Haifa (IL). **KEHAT,  
Izhak** [IL/IL]; 9 Horev Street, 34 341 Haifa (IL). **IT-  
SKOVITZ-ELDOR, Joseph** [IL/IL]; 42 SheErit HaPleta  
Street, 34 987 Haifa (IL). **AMIT, Michal** [IL/IL]; 261  
Yuvalim, 20 142 Misgav (IL).

(74) Agent: **G. E. EHRLICH (1995) LTD.**; 28 Bezalel Street,  
52521 Ramat Gan (IL).

(81) Designated States (*national*): AE, AG, AL, AM, AT (util-  
ity model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,  
CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (util-  
ity model), DE, DK (utility model), DK, DM, DZ, EC, EE  
(utility model), EE, ES, FI (utility model), FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,  
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,  
MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD,  
SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(88) Date of publication of the international search report:  
23 October 2003

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: METHODS OF GENERATING HUMAN CARDIAC CELLS AND TISSUES AND USES THEREOF

(57) Abstract: A method of generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype is disclosed. The method comprises (a) partially dispersing a confluent cultured population of human stem cells, thereby generating a cell population including cell aggregates; (b) subjecting said cell aggregates to culturing conditions suitable for generating em-  
bryoid bodies; (c) subjecting said embryoid bodies to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of said embryoid bodies, said culturing conditions suitable for inducing cardiac lineage differentiation including adherence of said embryoid bodies to a surface, and culture medium supplemented with serum, thereby generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype.



**WO 03/008535 A3**

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL02/00606

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12Q1/02; C12N 5/00, 5/02, 5/08; A01N 63/00; A61K 48/00

US CL : 435/29, 325, 366, 373, 377, 383, 392; 424/93.2, 93.21

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/29, 325, 366, 373, 377, 383, 392; 424/93.2, 93.21

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
EAST, CAPLUS, BIOSIS, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — Y	ITSKOVITZ-ELDOR, J. et al. Differentiation of Human Embryonic Stem Cells into Embryoid Bodies Comprising the Three Embryonic Germ Layers. Molecular Medicine. February 2000, Volume 6, No. 2, pp. 88-95, especially pages 92-93.	1-5, 10-19, 22, 23, 29-33, 38-47, 50, 51, 57-61, 66, 67, 74-82, 85, 86, 92, 93, 103, 105-110, 117-125, 128, 129, 135, 136, 180, 181, 186, 192-195 and 201  6-9, 20, 21, 24-28, 34-37, 48, 49, 52-56, 62-65, 68-73, 83, 84, 87-91, 94-102, 104, 111-116, 126, 127, 130-134, 137-179, 182-185, 187-191 and 196-200

☒ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"B" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

09 July 2003 (09.07.2003)

Date of mailing of the international search report

11 AUG 2003

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Facsimile No. (703)305-3230

Authorized officer

Deborah Crouch, Ph.D.

Telephone No. 703-308-0196

## INTERNATIONAL SEARCH REPORT

## C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HESCHELER, J. et al. Establishment of Ionic Channels and Signalling Cascades in the Embryonic Stem-Cell Derived Primitive Ectoderm and Cardiovascular System. Cells Tissues and Organs. 1999, Volume 165, No. 3-4, pp. 153-164.	1-201
A	ROBBINS, J. et al. Embryonic Stem Cells as a Model for Cardiogenesis. Trends in Cardiovascular Medicine. 1992, Volume 2, No. 2, pp. 44-50.	1-201
Y	KEHAT, I. et al. Long Term, high-Resolution, Electrophysiological Assessment of Human Embryonic Stem Cell Derived Cardiomyocytes: A Novel In Vitro Model for the Human Heart. Circulation. 31 October 2000, Vol. 102, No. 18, Supple. II, pp. II-4, see entire abstract.	1, 5-9, 11, 21, 22, 2729, 33-37, 39, 49, 50, 55, 57, 61-65, 84, 92, 97, 99-102, 103, 104, 108, 117, 127, 128, 133, 135, 140, 142-146, 150-154, 159, 170, 171, 176, 181, 182-185, 190, 194 and 199, 1-201
A	BALDWIN H. S. et al. Advances in Understanding the Molecular Regulation of Cardiac Development. Current Opinion in Pediatrics. 1999, Volume 11, pp. 413-418.	1-201



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☒ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**